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1. INTRODUCTION  
 
Cholecystokinin (CCK) belongs to the largest group of neuropeptides called 
brain–gut peptides. Originally CCK was discovered by Ivy and Oldberg in 1928 
as a hormone from duodenal mucosa mediating gallbladder emptying, and later 
by Harper and Raper in 1943 as a substance stimulating release of enzymes 
from the pancreas (Rehfeld and Nielsen 1995). Vanderhaeghen and colleagues 
(1975) established CCK in the vertebrate brain as a gastrin-like immunore-
activity and it is later considered as the most widely distributed neuropeptide in 
the mammalian central nervous system (CNS) (Noble et al. 1999). Electro-
physiological, biochemical and behavioural studies demonstrated that CCK acts 
as a neurotransmitter and neurmodulator in the brain. Neuronal CCK is found in 
numerous brain regions in varying concentrations and it is involved in neuro-
biology of several physiological and behavioural processes like regulation of 
feeding, anxiety, pain processing, perception, motivation, learning and memory. 
CCK serves as a co-transmitter for various mediators in the brain. The inter-
action of CCK with dopamine (DA) and opioid peptides (OP) has been most 
widely studied. Hökfelt and colleagues (Hökfelt et al. 1980a) discovered that 
the subpopulation of mesencephalic dopamine neurons projecting to limbic 
areas contains CCK. The distribution of both CCK and CCK type 2 receptors 
(CCK2R) parallels with that of endopioid peptides and opioid receptors in the 
brain (Gall et al. 1987; Ghilardi et al. 1992; Saito et al. 1980). In different fore-
brain areas (the amygdala, hippocampus and cerebral cortex) CCK is widely 
present in gamma aminobutyric acid (GABA) – and glutamatergic neurons 
containing cannabinoid type 1 receptors (CB1) (Marsicano and Lutz 1999). The 
physiological relevance of this co-localisation is not clear. The development of 
the genetically modified mice, lacking CCK2R (Nagata et al. 1996) has been a 
major step further in order to study the role of CCK in the brain, because the 
vast majority of effects of CCK in the brain were mediated via CCK2R. The 
close interaction of CCK with different neuromediator systems in the brain is 
the reason for the versatile impact of the genetic disruption of CCK2R on the 
behaviour of mice. The general goal of the present study was to analyze the 
phenotype of CCK2R deficient mice with particular emphasis on the dopamine, 
endopioids and endocannabinoids related functions by applying behavioural, 
pharmacological and molecular biological methods.  
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2. REVIEW OF LITERATURE 
 
2.1. Cholecystokinin (CCK) in the CNS 
Neuronal CCK is present in a variety of biologically active molecular forms 
(CCK-58, CCK-39, CCK-33, CCK-22, sulphated CCK-8 and CCK-7, un-
sulphated CCK-8 and CCK-7, CCK-5, and CCK-4) derived from a three exons 
consisting, single gene encoded 115-amino-acid pre-pro-CCK precursor 
molecule. CCK peptides are localised in neuron cell bodies as well as they are 
concentrated in the nerve endings (Rehfeld and Nielsen 1995). The highest 
density of CCK neurons is present in the cortical regions and CCK peptides are 
mainly in nerve processes throughout all the cortical layers. CCK peptides are 
expressed at high levels in specific subclasses of GABAergic interneurons. 
CCK’s mRNA is expressed in these GABAergic interneurons and also in 
pyramidal cells (Gallopin et al. 2006). The CCK positive pyramidal neurons are 
present in the neocortex in laminae II-IV (Toledo-Rodriguez et al. 2005). The 
hippocampal formation, amygdaloid nuclei, and hypothalamus are rich in CCK 
neurons. Other brain regions containing moderately developed networks of 
CCK neurons include the caudate nucleus and putamen, lateral septal nuclei, 
periaqueductal grey of midbrain and area postrema (Gallopin et al. 2006; 
Rehfeld and Nielsen 1995; Toledo-Rodriguez et al. 2005). CCK, like the other 
neuropeptides, is thought to be stored in dense core vesicles, located further 
away from the active zone and having different release properties and kinetics 
as compared to classical neurotransmitters (Zhu et al. 1986; Verhage et al. 
1991). Depolarisation of nerve terminals can trigger CCK release through Ca2+ 
dependent manner (You et al. 1994). Estrogens may have significant influence 
on the levels of CCK. CCK positive cells contain clusters of synaptic vesicles 
which are immunoreactive with estrogen receptor alpha, and estrogen is able to 
mobilize these vesicles closer to synapses (Hart et al. 2007). CCK levels 
fluctuate during the various stages of the estrous cycle (Hilke et al. 2007). 
Receptors for CCK have been classified by their relative affinity for the 
natural ligands, their differential distribution in tissues, and their molecular 
structure (Noble et al. 1999). The main characteristics of the CCK receptors 
have been listed in Table 1. The CCK type 1 receptors (CCK1R) bind sulphated 
CCK with a significantly higher affinity than sulphated gastrin or non-sulphated 
CCK. CCK2R bind gastrin and CCK with almost an equal affinity and 
discriminate poorly between the sulphated and non-sulphated CCK analogues. 
In the peripheral tissues CCK1R are presented in the pancreatic acinar cells and 
D cells of the gastric mucosa, smooth muscle cells of the gallbladder, pyloric 
sphincter, sphincter of Oddi, gastro-intestinal smooth muscles and enteric 
neuronal cells, and anterior pituitary corticotrophs (Crawley and Corwin 1994; 
Wank 1995). Peripheral CCK2R are located in the smooth muscle cells 
throughout the gastrointestinal tract, parietal, enterochromaffin-like D and chief 
cells of the gastric mucosa, myenteric plexus neurons, pancreatic acinar cells, 
monocytes and T lymphocytes (Wank 1995; Wank et al. 1994). The gastrin 
 12
receptor mediating acid secretion in the stomach was initially thought to be the 
third type of CCK receptor. However, so far only two CCK receptor genes have 
been cloned. The gastrin receptor corresponds to CCK2R located in the gastro-
intestinal tract and does not constitute the third type of CCK/gastrin receptor.  
 
 






Structure (human) 428 – aminoacid sequence 
protein (P32238 7TM) 
447 – aminoacid sequence 
protein (P32239 7TM) 
Splice variants No Long form, short form, 
∆form 
Genetically induced 
disruption of gene in 
mice  
(Kopin et al. 1999) (Nagata et al. 1996) 
Distribution  Gall bladder, pancreas, pylorus, 
intestine, spinal cord, vagus 
nerve, limited brain areas (nucl. 
tractus solitarius, area postre- 
ma, nucl. interpeduncularis, 
posteromedial part of nucl. 
accumbens) 
Throughout the brain (with 
the highest densities in the 
cerebral cortex, nucl. 
caudatus, anterolateral part 
of nucl. accumbens), vagus 
nerve, stomach, pancreas 
Endogenous ligands 
according to their 




CCK-8S ≥ gastrin, CCK-
8US, CCK-4  
Agonists  Caerulein (amphibian CCK 
analogues); A71623; GW5823; 
JMV-180 
Caerulein; CCK-4; Boc-
CCK-4; BC197; BC264; 
CCK-8US; gastrin; RB400 
Antagonists Proglumide; Lorglumide; 
Devazepide; Lintitript 









Gq/11; Gs Gq/11; Gs 
Functional effects  In peripheral stimulates: 
gallbladder contraction, 
secretion of pancreatic enzymes
In peripheral inhibits: 
gastric emptying, feeding, 
respiration  
dopamine–mediated behaviours 
and dopamine release in shell of 
nucleus accumbens 
In CNS stimulates: 
neuronal firing rate, 
nociception, anxiety, 
respiration 
In CNS inhibits: 
dopamine-mediated 
behaviours and dopamine 




In mammals the genes that encode CCK1R and CCK2R have been organized in 
a similar manner consisting of five exons and four introns. The receptor genes 
have homologous exon/intron splice sites. There are three different splice 
variants for CCK2R. Alternative splicing of exon 4 results in two transcripts 
that differ by five amino acids within the third intracellular loop. Although the 
shorter transcript is largely predominant in the stomach, to date, the 
physiological relevance of these isoforms is unknown (Noble et al. 1999; Song 
et al. 1993). CCK1R and CCK2R proteins are members of the G protein 
coupled receptor superfamily and as expected have seven transmembrane 
spanning domains (Dohlman et al. 1991) The protein sequences of both 
receptors contain at least three consensus sites for N-linked glucosylation and 
conserved cysteins in the first and second extracellular loops, which may form a 
disulfide bridge required for stabilisation of their tertiary structure (Silvente-
Poirot et al. 1998). In addition, there is one more cysteine in the C terminus, 
which may serve as a membrane-anchoring palmitylation site (Noble et al. 
1999; O'Dowd et al. 1988).  
The intracellular signal-transduction cascade of the CCK1R in pancreatic 
acinar cells is well known but it is rather poorly characterized for CCK2R, 
mainly because of the difficulty in working with isolated neurons or isolated 
gastric mucosa cells. Nevertheless, it has been shown that both CCK1R and 
CCK2R are coupled to a pertussis toxin-insensitive Gq protein family, which 
includes αq, α11, and α14 proteins and thereby they are able to activate 
phospholipase C (PLC). PLC cleaves phosphatidylinositol bisphosphate (PIP2) 
to form inositol trisphosphate (IP3) and diacylglycerol (DAG). IP3 binds to the 
intracellular ligand-gated Ca2+channels and thereby initiates the release of 
sequestered Ca2+. DAG activates protein-kinase C. The effect of CCK on 
neuronal excitability of pyramidal neurons in the enthorhinal cortex was 
studied, and the results showed that CCK increased firing frequency of neurons. 
This effect is mediated via CCK2R, involving G-proteins, PLC; and transient 
receptor potential channel 5 (Wang et al. 2011). CCK1R are coupled to the 
phospholipase A2/arachidonic acid pathways (Wu et al. 1997). It is likely that 
CCK1R are coupled with both Gs and Gq protein, because activation of CCK1R 
can also lead to an increase in the adenylyl cyclase signal transduction cascade 
(Marino et al. 1993; Yule et al. 1993). CCK might via CCK1R stimulate Ras, 
mitogen activated protein kinase (MAPKs) and c-Jun NH2-terminal kinase 
(JNKs) and due to that activate cell proliferation (Dabrowski et al. 1996; 
Tateishi et al. 1998). There is some evidence that CCK2R are also coupled to 
the MAPKs (Taniguchi et al. 1994), and to the arachidonic acid, activating 
pertussis toxin insensitive or sensitive G protein/phospholipase pathways 
(Pommier et al. 1999; Williams 2001). In the pancreatic cells CCK activates 
extracellular regulated kinase p44 and p42 (ERK1/2) by binding to CCK1R or 
CCK2R and it involves as well PKC-mediated activation of multiple forms of 
Raf (Seva et al. 1997; Williams 2001). CCK2R activation in the pancreatic cell 
line promotes cell survival through the induction of phosphoinositide 3-kinase 
and protein kinase B (PI3-K/PKB) signalling pathways (Todisco et al. 2001). In 
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the rat brain neuroblasts CCK induces, probably through CCK2R, activation of 
the intracellular signal cascade leading to tyrosine phosphorylation of the 
proteins and stimulation both the ERK1/2 and the PI3-K/PKB intracellular path-
ways involved in the cell survival and proliferation (Langmesser et al. 2007).  
 
 
2.2. Interaction of CCK with dopamine system 
Dopamine is a catecholamine synthesized from the essential amino acid tyrosine 
in common biosynthetic pathway with noradrenaline and adrenaline. It is a 
predominant catecholamine neurotransmitter in the mammalian central nervous 
system where it controls a variety of functions including cognition, emotion, 
locomotor activity, hunger, satiety and endocrine functions. The action of 
dopamine is mediated via five distinct (D1, D2, D3, D4 and D5) G protein-
coupled receptor subtypes. Two D1-like receptor subtypes (D1 and D5), coupled 
to the G-protein Gs, activate adenylyl cyclase and stimulate cAMP formation. 
Other receptor subtypes (D2, D3 and D4) belong to the D2-like receptor 





Figure 1. Distribution of DA neuron cell groups in the rodent brain in a schematical 
sagittal view. The principal projections of the DA cell groups are illustrated by arrows. 
A modified illustration from Bjorklund and Dunett (Bjorklund and Dunnett 2007). 
 
 
The mammal’s brain contains nine distinctive areas of dopamine neurons 
distributed from the midbrain to the olfactory bulb (Figure 1.). The numbering 
of these cell groups, from A8 to A16, was introduced in the classic study of 
Dahlström and Fuxe in 1964, and it is still valid (Dahlstrom and Fuxe 1964). In 
the midbrain the lateral A9 subgroup corresponds to neurons of the substantia 
nigra pars compacta (subNc), which have prominent projections to the dorsal 
striatum (the nigrostriatal dopaminergic pathway) and are involved in the 
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control of voluntary movement. The medially located A10 and A8 subgroups 
form the ventral tegmental area (VTA) and retrorubral field, respectively. 
Neurons in these subgroups prominently innervate the ventromedial striatum 
and prefrontal cortex, as part of the mesolimbic system, and are involved in the 
regulation of emotions and reward (Bjorklund and Dunnett 2007; Van den 
Heuvel and Pasterkamp 2008). Among the diencephalic and hypothalamic (A11 
to A15) areas the A12 group is located in the arcuate nucleus of the hypo-
thalamic median eminence and is involved in inhibitory control of the release of 
prolactin from the lactotroph cell in anterior lobe of the pituitary, but dopamine 
D2 receptors are also found in pituitary somatotroph, thyreotroph as well as in 
gonadotroph cells (Pivonello et al. 2007). Dopaminergic periglomerular cells in 
the olfactory bulb belong to the area A16 and interplexiform cells in retina to 
the area A17 (Marin et al. 2005).  
CCK is co-localized with dopamine in the most of dopaminergic neurons of 
the VTA projecting to the mesolimbic structures (Hökfelt, Rehfeld et al. 1980). 
The main CCKergic input of the nucleus accumbens (NAc) originates from the 
ventral midbrain. The accumbal rostral pole is equally innervated by CCK 
neurons projecting from both subNc and the ventral VTA, whereas the primary 
source of CCK innervation of the accumbal core is the VTA. Most of the 
CCKergic neurons projecting to any part of the accumbal compartments contain 
also DA (Lanca et al. 1998). CCK is shown to modulate dopaminergic neuro-
transmission in the mesolimbic structures. This interaction is complex and 
depends on the route of administration of CCK agonists and the subtype of 
CCK receptor involved (Altar and Boyar 1989; Crawley and Corwin 1994; 
Ladurelle et al. 1997). CCK1R are mostly localized in the caudal shell region of 
the NAc , whereas CCK2R are mostly localized in the rostral core in the NAc 
(Marshall et al. 1991). Pharmacological and behavioural studies demonstrate 
that CCK1R and CCK2R mediate the opposite effects of CCK on the activity of 
DA neurons in mice and rats. In general, in the caudal shell area of the NAc, 
CCK1R stimulation induces agonistic-like action on the effects of DA, such as 
increased firing of DA neurons (Carr and White 1986), potentiated K+-
stimulated DA release (Vickroy et al. 1988) and increased DA turnover (Kariya 
et al. 1994). Conversely, stimulation CCK2R in the rostral core area of the NAc 
has DA antagonistic-like effects, such as attenuated K+-stimulated DA release, 
decreased extracellular DA concentrations (Voigt et al. 1985) and turnover 
(Dahlstrom and Fuxe 1964; Voigt et al. 1985). CCK-8S reduces via CCK2R the 
apparent affinity of D2 agonists in the nucleus accumbens and caudate putamen 
(Li et al. 1995). Altar and colleagues showed that CCK2R activation suppresses 
both basal and augmented DA release. The increase in DA release after 
amphetamine administration is attenuated by the central administration of BOC-
CCK-4 or CCK-8US (the agonists of CCK2R) and by the central or systemic 
treatment with CCK-8S (Altar and Boyar 1989). On the other hand Ferrero and 
colleagues demonstrated that CCK-8S could via activation of the CCK2R 
receptor inhibit function of the pre-synaptic D2 receptors in nucleus accumbens 
and thereby reduce local DA release (Ferraro et al. 1996). CCK2R stimulation 
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opposes functionally as well the post-synaptic effects of DA in the nucleus 
accumbens (Weiss et al. 1989; Yim and Mogenson 1991). An additional 
indirect effect on dopaminergic functions of CCK is mediated via influence on 
the endopioid system. 
 
 
2.3. Opioid peptides in the CNS, interaction of CCK and 
dopamine with the endopioid system 
Opioid peptides (OP) are endogenous ligands for the opioid receptors (Evans 
2004). Pharmacological studies have defined three main opioid receptor 
subtypes, respectively mu, delta and kappa receptors. More than 20 different 
identified opioid peptides (Table 2) possess a diverse affinity and specifity for 
these three receptor types. All mammalian opioid peptides have an N-terminal 
enkephalin sequence (Tyr-Gly-Gly-Phe-Met/Leu), and are derived mainly from 
three opioid protein precursors pro-opiomelanocortin (POMC), proenkephalin, 
prodynorphin) by selective proteolytic cleavages predominantly at basic and 
paired basic residues. Each opioid peptide precursor has a unique pattern of 
expression, with pro-opio-melanocortin transcripts restricted mainly to the 
pituitary, the arcuate nucleus of the hypothalamus and some cells in the nucleus 
of the solitary tract, whereas both pro-enkephalin and prod-dynorphin have a 
considerably more widespread distribution and are located in the brain regions 
that regulate the extrapyramidal motor function, the cardiovascular and water 
balance system, eating, sensory processing, and pain perception (Peckys and 
Landwehrmeyer 1999).  
Opioid receptors are highly homologous to each other, have seven 
transmembrane-spanning domains and belong to the family of the G-protein 
coupled receptors (Zaki et al. 1996). There are suggestions that more than three 
opioid receptor genes could exist. However, despite that no other opioid 
receptor genes were identified by molecular cloning besides the opioid like 
receptor (ORL1 or NOP1) and this was not considered a classical opioid receptor 
since it did not bind the classical opioid receptor ligands such as naloxone. 
Endogenous ligand of these receptors, orphanin FQ is derived from a protein 
precursor different from other opioid peptides. Some other mechanisms, like 
RNA editing or different splicing, could create receptor diversity from single 
genes. Alternative splicing at the C-terminus has been observed in rodent mu-
receptor and this could provide heterogeneity in opioid receptor molecules and 
could modify receptor functioning, because this region is important in trans-































































































































































































































































































































































































































































































































































































































































































































































































































Opioidergic, dopaminergic and CCK-ergic systems are neuroanatomically and 
functionally closely related. Phasic dopamine release has been shown to 
increase endopioid levels (Roth-Deri et al. 2003), whereas tonic dopamine 
decreases endopioid levels (King et al. 2001; Zubieta et al. 2003) in NAc. 
Conversely, OP potentiate phasic DA release in the striatum by inhibiting local 
GABAergic interneurons in the VTA (Johnson and North 1992; Nugent et al. 
2007). The CCK and endopioid systems are in the antagonistic interaction if the 
regulation of behaviour is concerned. The administration of CCK attenuates, 
whereas the selective CCK2R antagonists enhance, morphine-induced anti-
nociception in rodents (Faris et al. 1983; Lavigne et al. 1992; Noble et al. 1995). 
CCK2R antagonists, but not CCK1R antagonists, facilitate the antidepressant-
like effect induced by opioid peptides in the conditioned suppression of motor 
activity in mice (Smadja et al. 1995). Moreover, the selective CCK2R anta-
gonists potentiate the rewarding effect of morphine in the place conditioning 
paradigm (Higgins et al. 1992; Valverde et al. 1996). The CCK2R antagonists 
L-365,260 and PD-134,308 are shown to attenuate the place aversion induced 
by naloxone in morphine-dependent rats, whereas the CCK1R receptor anta-
gonist devazepide is ineffective in this respect (Valverde and Roques 1998). A 
morphine-induced increase in the locomotor activity can also be antagonised by 
the pre-treatment with CCK (Schnur et al. 1991). These findings suggest that 
CCK may act, via CCK2R, as an endogenous anti-opioid peptide. It is also 
noteworthy that the distribution of both CCK and CCK2R parallels with that of 
OP and opioid receptors in the brain (Gall et al. 1987; Ghilardi et al. 1992; 
Saito et al. 1980). 
 
 
2.4. Endocannabinoids in CNS and interaction of CCK 
with endocannabinoid system 
The eCBs (anandamide and 2-arachidonylglycerol), endogenous ligands of the 
cannabinoid type 1 receptor (CB1) and cannabinoid type 2 receptor (CB2) 
receptors (Devane et al. 1992; Mechoulam et al. 1995; Sugiura et al. 1995), are 
produced from phospholipid precursors “on demand”, in a Ca2+-dependent 
manner when the neurons are stimulated with membrane-depolarizing agents 
(Di Marzo et al. 1994). The release of eCBs immediately follows their bio-
synthesis. The neuronal eCBs are inactivated by a rapid elimination process 
consisting of selective uptake into the cell and subsequent degradation by fatty 
acid amide hydrolase or monoacylglycerol lipase (van der Stelt and Di Marzo 
2003). CB1 receptors are abundant G-protein goupled receptors in the CNS. 
Activation of presynaptic CB1 receptors results in the inhibition of both 
excitatory and inhibitory neurotransmitter release. CB1 receptors can be located 
on several neurones, including GABA-, glutamate-, serotonin- and 
dopaminergic neurons (Freund et al. 2003; Szabo and Schlicker 2005; Pacher et 
al. 2006; Lazary et al. 2011; Umathe et al. 2011). CB1 receptors are also 
expressed in the periphery and are present in several non-neuronal tissues (e.g. 
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the gastrointestinal system, reproductive system, cardiovascular system, adipo-
cytes, liver, skeletal muscle cells and pancreas). These receptors are directly 
involved in the orexigenic effect of eCBs as well as in the regulation of 
metabolism, body weight as well as insulin resistance and are therefore the main 
targets in the development of new drugs for obesity and metabolic syndrome 
treatment (Cota et al. 2003). Rimonabant (SR141716A, Acomplia, Sanofi-
Aventis), the first selective CB1 antagonist or inverse antagonist (Rinaldi-
Carmona et al. 1994), was developed as an anti-obesity agent on the premise 
that blocking central eCB activity might reduce food intake (Pacher et al. 2006). 
The potent anti-obesity efficacy of rimonabant was demonstraeted by several 
clinical studies (Despres et al. 2009; Hampp et al. 2008), and dyslipidaemias, 
diabetes and metabolic syndrome were also ameliorated (Rosenstock et al. 
2008). Rimonabant was not only proposed for the treatment of obesity, meta-
bolic conditions as well as addictive disorders (smoking cessation) (Cahill and 
Ussher 2007; Rigotti et al. 2009). However, it induced significant psychiatric 
side effects, namely anxiety and depression, and therefore it was withdrawn 
from the European market in October 2008 (Kirilly et al. 2012). 
Cannabinoid type 2 receptors (CB2) are expressed in the immune system and 
in the brain microglia during neuro-inflammation. CB2 receptor was isolated by 
a PCR-based strategy designed to isolate GPCRs in differentiated myeloid cells. 
The CB2 has 44% amino acid identity with CB1, and a distinct yet similar 
binding profile, and thus represents a distinct receptor subtype (Munro et al. 
1993). CB1 and CB2 receptors belong to the seven-transmembrane G-protein 
coupled receptor family. Their activation typically leads to the inhibition of 
adenylate cyclase, consequently closing calcium channels, opening potassium 
channels and stimulating protein kinase A (Freund et al. 2003). 
Like CCK eCBs take part in the modulation of feeding behaviour, 
behavioural expression of anxiety, pain, learning and memory (Noble et al. 
1999; van der Stelt and Di Marzo 2003). In various forebrain areas (the 
amygdala, hippocampus and cerebral cortex) CCK is widely present in GABA- 
and glutamatergic neurons containing CB1 receptors (Marsicano and Lutz 
1999). The functional interaction between CCK and eCBs seems to be in most 
cases antagonistic. eCBs can function as retrograde messengers in the synaptic 
level (Chhatwal et al. 2009), reducing via CB1 receptors the excitability of 
presynaptic neurons. Indeed, the activation of CB1 receptors has been shown to 
inhibit potassium-evoked CCK release in the hippocampus (Beinfeld and 
Connolly 2001).  
 
 
2.5. Phenotype of CCK2 receptor deficient mice 
Our study was performed on gene targeted CCK2R deficient mice line 
(CCK2R-/-), with original background of 129Sv/C57Ll/6 and which were 
originally generated by replacing a part of exon 2 and exons 3, 4 and 5 (Nagata 
et al. 1996). The adult CCK2R-/- mice are fertile, have a normal body weight 
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and are without obvious abnormalities in their general appearance in com-
parison with their wild-type littermates (CCK2R+/+). CCK2R mRNA is absent 
in total RNA samples extracted from the CCK2R-/- mice cerebral cortex, brain 
basal ganglia and stomach, which abundantly express this transcript in the 
CCK2R+/+ mice examples. The lack of a functional CCK2R protein in whole 
brain and pancreas preparations was proved by 125I-CCK-8 binding assay. 
CCK2R/gastrin receptors on the gastric parietal cells have an important role on 
the regulation of gastric acid secretion. A marked atrophy in the CCK2R-/- 
samples became evident in the macroscopic and histological studies of the 
gastric mucosa. The number of parietal cells was decreased in the fundic glands 
and the expression of H+,K+-ATPase mRNA was significantly reduced in the 
parietal cells. The basal gastric acid output in the CCK2R-/- mice was re-
markably inhibited compared with that of the CCK2R+/+ mice and as expected, 
serum gastrin levels in the adult CCK2R-/- mice, fasted for 6 hr, were about 5 
times higher than those in the wild-type mice (Nagata et al. 1996). The gastric 
emptying with a non-nutrient liquid load was investigated and it was signifi-
cantly enhanced in the CCK2R-/- mice as compared with wild type littermates 
(Miyasaka et al. 2004).  
The effect of CCK2R deficiency in memory process was studied in a Y 
maze. During the two-trial recognition memory task after a 2 hr inter-trial 
interval, wild-type mice spent significantly more time in the novel arm than 
mutant mice, indicating a decreased performance of mutant mice group (Sebret 
et al. 1999).  
The CCK2R deficient mice showed an increased spontaneous locomotor 
activity and the administration of the D2 selective antagonist sulpiride 
completely abolished this effect (Dauge et al. 2001). By the Western blot 
analysis the dopamine D2 receptor expression in the nucleus accumbens was 
studied and it was significantly lower in the CCK2R-/- than in wild type male 
mice (Miyasaka et al. 2005).  
The existence of physiologically relevant interactions gives a reason to 
analyse the effect of CCK2R gene invalidation on the endopioid system. The 
absence of negative feedback control in genetically modified mice, normally 
performed by CCK2R stimulation, results in an up regulation of the endopioid 
system with a positive coupling of the µ and δ opioid receptors to the adenylyl 
cyclase pathway. It was evidenced with an increased locomotor response to the 
administration of morphine or the enkephalin-degrading enzyme inhibitor RB 
101. Moreover, much more severe withdrawal syndrome was observed in these 
genetically modified animals after chronic morphine treatment. These mice 
showed spontaneous hyperalgesia and hyposensitivity toward the anti-
nociceptive effects of morphine and RB101 in the hot-plate jump latency test 
(Pommier et al. 2002). A reduced pain sensitivity of CCK2R deficient mice in 
the plantar analgesia and hotplate tests was established by Veraksitš and 
colleagues (Veraksitš et al. 2003). However, in this study CCK2R deficient 
mice seemed to have a reduced tolerance to painful stimuli as measured by the 
jump latency in the hotplate test. In the plantar analgesia test the antinociceptive 
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action of morphine is significantly stronger in mutant mice, whereas in the 
hotplate test the effect of morphine remained unchanged compared with wild-
type littermates. The repetitive administration of morphine results in an easier 
development of motor sensitization in the CCK2R-/- group (Dauge et al. 2001).  
CCK is implicated in the regulation of anxiety and anxiogenic-like action of 
CCK agonists is mediated via CCK2R (Noble et al. 1999). The activity of 
GABA-ergic system is increased in the brain of mice lacking CCK2R. Female 
CCK2R-/- mice displayed an increased exploratory activity in the dark-light 
exploration test (Raud et al. 2005) and elevated plus-maze (Areda et al. 2006; 
Raud et al. 2003). The wild-type littermates displayed higher sensitivity to the 
anxiolytic-like action of diazepam compared to the homozygous CCK2R-/- 
animals (Raud et al. 2005; Raud et al. 2003). The administration of methyl-6,7-
dimethoxy-4-ethyl-beta-carboline-3-carboxylate (DMCM) an inverse agonist of 
benzodiazepine receptors, caused opposite changes in the exploratory behaviour 
of the wild type and CCK2R-/- female mice in the dark-light exploration test. An 
increase in exploratory activity was established in the female wild-type animals, 
by contrast, the administration of DMCM caused a dose-dependent reduction of 
exploratory behaviour in the CCK2R-/- female mice (Raud et al. 2005). The 
anxiogenic-like effect of cat odour was studied and it was found that the 
exposure to cat odour caused a significant anxiogenic-like action in the CCK2 
receptor deficient female mice. This effect was not seen in the wild-type female 
animals, displaying a significantly lower exploratory activity in the plus-maze 
(Areda et al. 2006). The higher exploratory activity of the CCK2R deficient 
female mice was accompanied by an increased expression of mu-opioid 
receptor and CCK1R mRNA in the frontal cortex and midbrain. The CCK gene 
expression was reduced in the frontal cortex and mesolimbic area of female 
mice, lacking CCK2R (Areda et al. 2006). In the CCK2R-/- female mice group, 
after the exposure of cat odour, some significant alterations in the gene expres-
sions were established. The increase of POMC gene was remarkable in the 
temporal lobe, mesencephalon and mesolimbic area. Cat odour exposure 
elevated the expression of the melanocortin type 3 receptor gene in the temporal 
lobe and frontal cortex of homozygous mutant female mice. In the temporal 
lobe cat odour also increased the expression of delta opioid receptors and pro-
enkephalin genes in homozygous female mice (Areda et al. 2006). It has been 
shown that the CCK2R–/– mice do not develop eCB-sensitive stress induced 
analgesia, because the analgesic response is antagonized by opioid antagonist 
naloxone, but not by CB1 receptor antagonist rimonabant. The stress, induced 
by inescapable electric foot-shocks, caused up-regulation of eCB-related genes 
in the lumbar spinal cord and mesolimbic area of wild-type mice, whereas no 
change occurred in the CCK2R–/– animals (Kurrikoff et al. 2008). 
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3. AIMS OF THE STUDY  
 
Based on the literature review it is clear that CCK closely interacts with various 
neuromediator systems in the brain and, therefore, the genetic invalidation of 
CCK2R could have versatile impact on the behaviour of mice. In order to 
extend our pool of knowledge about the role of CCK in the regulation of 
behaviour the following specific tasks were put forward: 
1. To study the impact of CCKergic mechanisms on functional, neurochemical 
and molecular characteristics of brain dopaminergic neurons. 
2. To describe whether invalidation of CCK2R in mice changes the activity of 
endopioid system and adaptive behaviour in mice. 
3. To determine the functional role of eCB-s in the development of ampheta-
mine induced sensitization and possible involvement of CCK2R. 
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4. MATERIALS AND METHODS 
 
4.1. Animals 
The CCK2R deficient mice with original background 129 Sv/C57Bl/6 were 
generated by replacing a part of exon 2 and exons 3, 4 and 5 (Nagata et al. 
1996). Breeding and genotype analysis were performed at the Department of 
Physiology of the University of Tartu. Genotyping was carried out by means of 
polymerase chain reaction (PCR) using two pairs of primers – HE2F (TGG 
AGT TGA CCA TTC GAA TCA C) and LacZrev (GTG CTG CAA GGC GAT 
TAA GTT G) were designed to detect the mutant allele, and HE3F (TAT CAG 
TGA GTG TGT CCA CTC T) and HE3R (ACA TTT GTT GGA CAC GTT 
CAC) were designed for the wild-type allele. The following protocol was used 
for PCR: 96oC for 10 min (initial denaturation); 96oC for 50 s, 60oC for 50 s, 
and 72oC for 2 min (25 cycles); and 72oC for 10 min (final amplification). PCR 
products were stored at 4oC until electrophoresis. Mutant mice were crossed 
back three times (paper I) six times (paper II), ten times (paper III) and twelve 
times (paper IV) to the C57Bl/6 background to minimize any possible genetic 
effects from the 129sv strain. Altogether 377 male homozygous CCK2R-/-, 98 
male heterozygous CCK2R+/- and 381 male wild-type CCK2R+/+ adult (3–5 
months old) mice were used in the behavioural and radioligand binding studies. 
The heterozygous CCK2R+/- mice were used only in the first study. In the 
following studies we reduced the number of animals used in experiments and 
compared only the homozygous CCK2R-/- and the wild-type CCK2R+/+ mice. 
The mice were kept in the animal house at 20±2oC under a 12-h/12-h light/dark 
cycle (lights on at 0700). Tap water and food pellets were available ad libitum. 
All animal procedures were approved by the Animal Care Committee of the 
University of Tartu in accordance with the European Communities Directive of 




All drug solutions were administered intraperitoneally in volume 10 ml/kg. 
Amphetamine sulphate (Sigma) (Papers I, III and IV), apomorphine hydro-
cloride (Sigma) (Paper I), morphine sulphate (Boehringer-Ingelheim) (Paper II), 
and naloxone hydrochloride (Sigma) (Paper II), were dissolved in sterile, 
pyrogen free, 0,9% solution of sodium chloride in water (saline). Rimonabant 
(Sanofi–Aventis) was dissolved in vehicle (saline, 5% dimethyl sulphoxide, and 
a few drops of Tween-80) (Paper IV). 
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4.3. Analysis of dopamine and its metabolites  
in the mouse brain samples (Paper I) 
Mice were decapitated; the brains were rapidly removed and cooled in liquid 
nitrogen. The following brain areas were dissected from the sections according 
to the Franklin and Paxinos Mouse Brain Stereotaxic Atlas (Paxinos 1997): the 
cerebral cortex, both striata, and the hypothalamus. The dissected tissues were 
frozen in liquid nitrogen and stored at –80°C until sample preparation. The 
brain samples were homogenised in 10–50 volumes of 0.1 N HClO4, depending 
on tissues. The homogenates were centrifuged at 16,500 rpm (15 min +4°C, 
Heraeus Sepatech, Biofuge 17RS). The supernatant was removed, separated into 
two individual Eppendorf tubes and stored at –80°C until analysed. Two 
different high-performance liquid chromatography (HPLC) runs determined DA 
and their metabolites: one assay for DA and its metabolite dihydro-
xyphenylacetic acid (DOPAC), and another assay for measuring homovanillic 
acid (HVA). Both chromatographic systems consisted of an isocratic Waters 
510 pump (Waters), a Waters 717 plus auto-sampler with cooler (Waters), a 
reverse-phase C18 column (Ultrasphere ODS, 4.6×250 mm, 5 µm particle size, 
Beckmann) and Hewlett Packard HP-3396A integrators. In the HPLC system 1, 
the detector (ESA Coulochem II, ESA) was equipped with a 5021 (ESA) 
conditioning cell and a two-channel (Det 1 and Det 2) 5011 (ESA) analytical 
cell. The potentials applied were +0.10 V (conditioning cell), +0.375 V (Det 1) 
and –0.350 V (Det 2). The sensitivities were set at 100 nA (Det 1) and 5 nA 
(Det 2). In the HPLC system 2, the detector (ESA Coulochem 5100A, ESA) 
was equipped with a 5021 conditioning cell (+0.10 V) and a 5014A analytical 
cell (+0.35 V, Det 1). The sensitivity was set at 15×100. The detection limits 
were 18 fmol for DA and DOPAC in HPLC 1 and 100 fmol for HVA in HPLC 
2. The mobile phase consisted of a sodium acetate buffer (0.1 M), citric acid 
(0.1 M), methanol (7.5%) and sodium octyl sulphate 45 mg/l for the first HPLC 
method and 90 mg/l for the second. The pH of the mobile phase was adjusted to 
3.6 with phosphoric acid, and the flow rate was 1.1 ml/min. 
 
 
4.4. Radioligand binding studies (Papers I and II) 
The mice used in the radioligand binding study were not exposed to the 
behavioural testing. After the decapitation of mice their brains were quickly 
dissected on ice. The striatum and mesolimbic structures were used for studying 
the parameters of dopamine D2 receptors, whereas the cerebral cortex was used 
for serotonin 5-HT2 receptor studies (paper I). The opioid receptors were 
analysed in the cerebral cortex (including the frontal and parietal cortices), the 
striatum, mesolimbic (nucleus acumbens and tuberculum olfactorium) and the 
hippocampus (paper II). The dissected tissues were frozen and stored at –80oC 
until sample preparation. The radioligand binding studies were performed in 
accordance with the method described by Kõks and colleagues (Kõks et al. 
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1997). Each experiment was repeated at least three times. The brain structures 
from six mice were pooled. The brain tissue was homogenized in 20 volumes of 
ice-cold 50 mM Tris-HCl (pH 7.4 at 4o C) using a Potter-S glass-teflon 
homogenizer (1000 rpm, 12 passes). The membranes were washed twice in the 
same buffer by centrifugation (48000  g for 20 min) and re-suspension. After 
the last centrifugation crude brain membranes were suspended in an appropriate 
incubation buffer at the concentration of 10 mg wet weight/ml. After the 
incubation time the binding reaction was determined by rapid filtration over 
Whatman GF/B filters, thereafter washed with 9 ml ice-cold buffer. The filters 
were dried and left overnight in a Wallace High Safe III scintillation cocktail. 
Radioactivity was assayed by liquid scintillation spectrometry (Wallac -
scintillation counter) at 50 per cent efficiency level. The protein content was 
measured according to the Bradford method (Bradford 1976). The saturation 
curves of radioligand binding were analysed by using GraphPad Prism (Version 
3.00) for Windows software.  
 
 
4.4.1. [3H]-spiperone binding for serotonin (5-HT2A) and  
dopamine (D2) receptors (Paper I) 
After final washing the crude brain membranes were homogenised in the 
incubation buffer consisting of 50 mM Tris; 120 mM NaCl; 5mM KCl; 2 mM 
CaCl2; 1 mM MgCl; pH 7,4 adjusted with HCl. The parameters of dopamine 
and serotonin receptors were determined in the presence of 0.06–2 nM [3H]-
spiperone (specific activity 107 Ci/mmole) (Amersham Radiochemicals) 
incubated at 37oC for 30 min. Raclopride (1 M) (Astra), an antagonist of 
dopamine D2, was added to determine the non-specific binding of dopamine D2. 
Ritanserin (1M) (RBI), an antagonist of 5-HT2, was used to detect the non-
specific binding of 5-HT2. 
 
 
4.4.2. [3H]-diprenorphine binding for opioid receptors (Paper II) 
After the last centrifugation in the washing step the crude brain membranes 
were resuspended in the incubation buffer (50 mM Tris; 120 mM NaCl; 5mM 
KCl; 2 mM CaCl2; 1 mM MgCl; pH 7.4 adjusted with HCl). The parameters of 
the opioid receptors were determined in the presence of 0.05–2.5 nM [3H]-
diprenorphine (specific activity 58.0 Ci/mmole) (Amersham Radiochemicals) at 
23oC for 60 min. Naloxone hydrochloride (1 µM) (RBI), an antagonist of opioid 




4.5. Gene expression analysis (Paper III) 
In gene expression studies, quantitative real-time PCR (qPCR) was applied. The 
animals used for the behavioural sensitization experiment were exploited in this 
study. Forty-eight hours after the last amphetamine or saline injection mice 
were killed with cervical dislocation. Three brain areas (the striatum, the 
mesolimbic area and the mesencephalon) were quickly dissected on ice. For the 
dissection of the striatum and the mesolimbic area the first transverse section 
was made at the level of the chiasma opticum. The second transverse section 
was performed 2 mm anterior from the line crossing the chiasma opticum. The 
dissection of the striatum and the mesolimbic area was performed according to 
the coordinates of the Franklin and Paxinos Mouse Brain Stereotaxic Atlas 
(Paxinos 1997). The mesolimbic area includes the NAc, VP, tuberculum 
olfactorium, and the islands of Calleja. For the dissection of the mesencephalon, 
the cerebellum was removed and the first transverse section was made at the 
level of the posterior border of the corpora quadrigemina (colliculus inferior). 
The second transverse section was made behind the posterior border of the 
hypothalamus. The mesencephalon includes a number of various structures (the 
corpora quadrigemina, periaqueductal gray, oculomotor nuclei, etc.), but for the 
purposes of our study two nuclei containing dopaminergic neurons (substantia 
nigra and the VTA) are especially important. The dissected tissues were frozen 
in liquid nitrogen and stored at −80 C until sample preparation. Total RNA was 
extracted using TRIzol-Reagent (Invitrogen) according to the manufacturer’s 
protocol. Total RNA from different animals of each group was pooled. Pooling 
was performed to minimize the fluctuations resulting from individual diffe-
rences. Every experimental group (n=13) was pooled as follows: three pools 
including samples from three mice and one pool including samples from four 
animals. Consequently, the number of independent samples in each case was 
four. Forty-eight different pools of total RNA (three brain structures, four 
groups of animals and four samples) were received. As a rule, experiments with 
wild-type and homozygous mice were conducted in parallel. The first strand 
cDNA was synthesized using SuperScript III reverse transcriptase (Invitrogen). 
The expression levels of the following gene transcripts were measured: 
catechol-O-methyltransferase (Comt), monoamine oxidase A (Mao), tyrosine 
hydroxylase (Tyhy), dopamine D1 receptor (Drd1) and dopamine D2 receptor 
(Drd2) (primers have been presented in Table 3.). The qPCR was performed 
using ABI Prism 7900 Sequence Detection System (PE Applied Biosystems) 
equipment and ABI Prism 7900 SDS Software. We used SYBR green I qPCR™ 
Core Kit (Eurogentec) for all reactions. PCR was set up by the following steps: 
95 C for 10 min; 95 C 15 s and 60 C for 1 min, repeated for 40 cycles. Melting 
curve analysis of the amplification product was performed at the end of each 
reaction to confirm the quality of the PCR. All reactions were performed in the 
final volume of 10 μl, using 50–100 ng of cDNA. Mouse hypoxanthine–guanine 
phosphoribosyl transferase (Hprt) was used as a housekeeper gene (Table 3.). 
Hprt was chosen as an endogenous reference gene because it is a constitutively 
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expressed gene in the mammalian brain. Primers were designed with the help of 
Primer Express™ software (PE Applied Biosystems) to anneal to the different 
exons in order to avoid possible amplification of genomic DNA. The amount of 
the target gene was compared to the housekeeper gene in the experimental 
group and in the control group by means of the comparative ΔCT method (Livak 
and Schmittgen 2001). The mRNA level in the saline-treated wild-type control 




Table 3. Primer sequences used for qRT-PCR 




   
Mao 
Forward: 5'-GCCAAGAAGGATATATGGGTTCAA-3' 
Reverse: 5'-GAGCTGGAACATCCTTGGACT C-3' 



















4.6. Behavioural experiments (Papers I, II, III and IV) 
The animals were brought into the experimental room one hour before the 
experiment. All behavioural experiments were performed between 11:00 a.m 
and 7:00 p.m. The motility and conditioned place preference tests were 
performed on separate animal groups. Since the behavioural experiments lasted 
for 6–8 h, precautions were taken to control possible daily fluctuations in the 
animals’ locomotor activity. Therefore, the experiments were always performed 
in randomized order, that is, wild-type mice were always used in parallel with 




4.6.1. Locomotor activity test (Papers I and II) 
The locomotor activity of mice was studied in the photoelectric motility boxes 
(448 x 448 x 450 mm) connected to a computer (TSE Technical & Scientific 
Equipment GMBH). The illumination level in the transparent test boxes was 
~400 lux. The apparatus-naïve mice were placed individually in the chambers, 
and vertical and horizontal activity was registered during a 30-min (I; II and III 
paper) or a 10-min (IV paper) observation period. After removing a mouse from 
the box the floor was cleaned by using 5 % alcohol solution. All the tests were 
carried out with different animal groups. Amphetamine was injected 
intraperitoneally 20 min; apomorphine, morphine, and naloxone 15 min before 
the measurement. The mice were pre-adapted to the motility boxes for three 
days before morphine (5 mg/kg; 10 mg/kg), an opioid receptor agonist was 
administered. The effect of naloxone (1 mg/kg; 10 mg/kg), an unselective opiate 
receptor antagonist, was studied both in mice pre-adapted and not adapted to the 
motility boxes (II paper). The locomotor effects of amphetamine (3 mg/kg and 
an unselective agonist of dopamine D1 and D2, were studied in the animals not 
adapted to the test situation (I paper).  
 
 
4.6.2. Behavioural sensitization (Papers III and IV) 
The behavioural sensitization experiments were carried out in the photoelectric 
motility boxes (448 x 448 x 450 mm) connected to a computer (TSE Technical 
& Scientific Equipment GMBH). The illumination level of transparent test 
boxes was ~400 lux. All the animals were pre-adapted to the motility boxes and 
their motor activity was measured for three consecutive days before the sensiti-
sation procedure was initiated. CCK2R+/+ and CCK2R-/-mice were randomly 
divided into treatment groups. In the first paper there was a saline-treated 
control group and amphetamine- (1 mg/kg) treated group (paper I). Immediately 
after the administration of saline or amphetamine the mice were placed into the 
motility box and their motor activity was recorded. In the sensitization experi-
ment, described in the paper IV, the mice were at first administered vehicle or 
rimonabant (1 mg/kg) and then placed into their home cages. Thirty minutes 
later, the animals were administered saline or amphetamine (2 mg/kg) and then 
placed into the motility box and their motor activity was recorded for the 
subsequent 30 min. All the animals were treated for four consecutive days. The 
motor activity of mice on the first and fourth day of the experiment was 
compared in order to evaluate their motor sensitisation to amphetamine (1 or  
of withdrawal, all the mice were treated with amphetamine (2 mg/kg), and their 
motor activity was measured for the subsequent 30 min.  
 
 
6 mg/kg), increasing the release of catecholamines and apomorphine (0.1 mg/kg), 
2 mg/kg). In the sensitization experiment, described in the paper IV, after 21 days 
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4.6.3. Place preference conditioning test (Paper III) 
The place preference conditioning experiment were performed in three identical 
shuttle boxes (50 x 25 x 30). Each shuttle box was divided into two compart-
ments of equal size by a sliding door having partition. The door allows free 
movement of a test animal between the two compartments if opened or restricts 
the movement of a mouse to the other compartment if closed. These compart-
ments were distinguished by wall and floor colour (dark green versus pale 
green). The illumination level in the experiment room was ~200 lux. Each 
experiment consisted of pre-conditioning, conditioning, and post-conditioning 
periods. During the pre-conditioning period mice were placed three times into 
the apparatus for 15 minutes. The first and the second pre-conditioning tests 
were held on day 1. The third pre-conditioning test was held on day 2 of the 
experiment, and the time spent in the pale green compartment was measured. 
During the pre-conditioning and post-conditioning tests, the animals were 
allowed to explore both compartments freely. Each pre- and post-conditioning 
session began with an animal’s initial placement into the dark green compart-
ment. The shuttle boxes were cleaned carefully by 5% ethanol solution after 
each animal. The conditioning period consisted of 30-min experimental session 
performed twice a day for four consecutive days (days 3–6). Animals’ move-
ments were restricted into one compartment of the shuttle boxes. Every day 
animals received a saline injection as a first injection before being placed into 
one compartment and during the second session of the day, before their place-
ment into the opposite compartment, they were injected with amphetamine  
(1 mg/kg; 2 mg/kg and 3 mg/kg). In the pre-conditioning session (days 1–2), the 
animals clearly preferred the dark green side and, therefore, the injections of 
amphetamine were paired with the pale green side avoided by mice during the 
pre-conditioning session (conditioning of place preference). The control group 
of animals received their injection of saline in both compartments. Injections 
were given immediately before the conditioning sessions. Fifteen-minute post-
conditioning tests were performed on day 7 of the experiments and the time 
spent in the pale green side of the shuttle box was measured.  
 
 
4.7. Statistics  
The results have been expressed as mean values ± S.E.M. The behavioural and 
gene expression studies were analysed by using analysis of variance (ANOVA) 
or multivariate analysis of variance (MANOVA). Post hoc comparisons 
between means of the individual groups were performed by Tukey HSD or 
Newman-Keuls test (Statistica for Windows software). The student’s t-test was 





5.1. Locomotor activity test (Papers I and II) 
5.1.1. Effect of apomorphine (Paper I)  
The administration of a low dose of apomorphine (0.1 mg/kg), an unselective 
agonist of DA receptors, reduced the locomotor activity [one-way ANOVA: 
distance in locomotion F5,42=10.88, P<0.01,). The application of two-way 
ANOVA did not reveal any statistical differences when the genotype and 
treatment data were compared (Paper I). However, in mutant animals, the motor 
suppressant effect of apomorphine was stronger than in the wild-type mice, since 
the DA agonist reduced not only the distance travelled and corner entries but also 
the number of rearing (one-way ANOVA:  F5,42=5.87, P<0.01) (Figure 2).  
 
 
Figure 2. Apomorphine (0.1 mg/kg) induced motor suppression in cholecystokinin 
CCK2R receptor-deficient mice. The number of animals in each group was 8. White 
bars saline, black bars apomorphine. +P<0.05 (compared with the respective saline-




5.1.2. Effect of amphetamine (Paper I) 
The applying of two-way ANOVA (genotype; treatment) established 
statistically significant differences when the effect of amphetamine (3 mg/kg 
and 6 mg/kg) was compared between the wild-type CCK2R+/+ and the CCK2R-/- 
mice (ANOVA: distance in locomotion F4,117=5.85, P<0.01; F4,117=2.90, 
P<0.05). The administration of amphetamine (3 mg/kg and 6 mg/kg) to the 
CCK2R+/+ mice induced a dose-dependent increase in locomotor activity 
(Figure 3.). A lower dose of amphetamine (3 mg/kg) slightly, but insignifi-
cantly, increased the locomotion in the CCK2R+/- mice, but not in the 
homozygous CCK2R-/- animals. The higher dose of amphetamine (6 mg/kg) 
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caused a significant increase in the locomotor activity in mutant mice. In the 
CCK2R+/- heterozygous mice, the effect of amphetamine (6 mg/kg) did not 
differ from that in the wild-type CCK2R+/+ littermates; whereas, in the homo-
zygous CCK2R-/- mice, the higher dose of amphetamine caused the significantly 





Figure 3. Amphetamine (3 and 6 mg/kg) induced motor stimulation in cholecystokinin 
(CCK)2R deficient mice. The number of animals in each group was 14. White bars 
saline, striped bars amphetamine 3 mg/kg, black bars amphetamine 6 mg/kg. +P<0.05 
(compared with the respective saline-treated group; Tukey HSD test after two-way 
analysis of variance), *P<0.05 (compared with the respective wild type group). 
 
 
5.1.3. Locomotor adaptation (Paper II) 
In the first adaptation session the locomotor activity of mutant mice did not 
differ from that of wild-type littermates (Figure 4.). Only the number of rearing 
was somewhat higher in homozygous CCK2R-/- animals. However, during the 
third adaptation session some obvious differences became evident. There was a 
significant reduction of locomotor activity in the wild-type mice but not in the 
homozygous CCK2R-/- mice. The wild-type animals displayed a significant 
reduction of time in locomotion (two-way ANOVA: genotype F1,28=10.43, 
P<0.01; experiment F1,28=20.1, P<0.01; genotype  experiment F1,28=7.46, 
P<0.01), distance travelled (two-way ANOVA: genotype F1,28=5.91, P<0.05; 
experiment F1,28=20.1, P <0.01; genotype  experiment F1,28=6.56, P<0.05) and 
the number of corner entries (two-way ANOVA: genotype F1,28=1.36, P=0.25; 
experiment F1,28=19.3, P<0.01; genotype  experiment F1,28=5.15, P<0.05) 
compared with the homozygous CCK2R-/- animals (Figure 4.). The application 
of two-way ANOVA did not establish any significant differences in the 
frequency of rearing (genotype F1,28=25.17, P<0.01; experiment F1,28=5.17, 




Figure 4. Different adaptation of wild-type mice and mice without CCK2R in the 
motility boxes. The number of animals in each group was 25. White bars – the motor 
activity of mice during the first experiment, black bars – the response of animals during 
the third experiment. (*) P < 0.05; (**) P < 0.001 (compared with the first experiment, 
Tukey HSD test after the significant two-way ANOVA); (+) P < 0.05 (compared with 
the respective group of wild-type mice). 
 
 
5.1.4. Effect of morphine (Paper II) 
The administration of morphine (5–10 mg/kg) induced strong motor stimulation 
in the wild-type CCK2R+/+ mice habituated to the motility boxes (Figure 5.). 
This effect was not established in the homozygous CCK2R-/- animals habituated 
to the experimental environment. A lower dose (5 mg/kg) of morphine did not 
affect markedly the motor activity of the wild-type CCK2R+/+ mice, whereas a 
higher dose (10 mg/kg) increased the time in locomotion (two-way ANOVA: 
genotype F1,42=0.39, p=0.39; treatment F2,42=11.1, P<0.01; genotype  
treatment F2,42=5.40, p<0.01), the distance travelled (two-way ANOVA: 
genotype F1,42=0.17, P =0.90; treatment F2,42=14.8, P<0.01; genotype  
treatment F2,42=4.29, P<0.05), the number of rearing (two-way ANOVA: 
genotype F1,42=1.70, P=0.20; treatment F2,42=6.7, P<0.01; genotype  treatment 
F2,42=4.81, P<0.05) and the frequency of corner entries (two-way ANOVA: 
genotype F1,42=1.19, P=0.28; treatment F2,42=19.0, P<0.01; genotype  




Figure 5. The effect of morphine (5 and 10 mg/kg i.p.) on the locomotor activity of mice 
without CCK2 receptors. The number of animals in each group was 17. White bars – 
saline treatment, striped bars – morphine (5 mg/kg), black bars – morphine (10 mg/kg). 
(*) P < 0.05 (compared with the respective saline-treated group, Tukey HSD test after 




5.1.5. Effect of naloxone (Paper II) 
The administration of opioid receptor antagonist naloxone (1 and 10 mg/kg) to 
non-habituated mice induced a dose-dependent reduction of the locomotor 
activity in the wild-type CCK2R+/+ and homozygous CCK2R-/- mice (Figure 6). 
However, the application of two-way ANOVA did not reveal any significant 
differences if the action of naloxone was compared in the wild-type CCK2R+/+ 
and mutant animals. Naloxone induced a decrease of time in locomotion (two-
way ANOVA: genotype: F1,42=0.95, P=0.76; treatment: F2,42=8.91, P<0.01; 
genotype × treatment: F2,42=0.87, P=0.42), distance travelled (two-way 
ANOVA: genotype: F1,42=0.09, P=0.77; treatment: F2,42=12.13, P<0.01; 
genotype × treatment: F2,42=1.21, P=0.30), number of rearing (two-way 
ANOVA: genotype: F1,42=7.94, P<0.01; treatment: F2,42=6.44, P<0.01; 
genotype × treatment: F2,42=1.06, P=0.35) and frequency of corner entries (two-
way ANOVA: genotype: F1,42=3.05, P=0.09; treatment: F2,42=12.6, P<0.01; 
genotype × treatment: F2,42=1.79, P=0.17). Nonetheless, the usage of post-hoc 
analysis demonstrated that the administration of naloxone (1 and 10 mg/kg) 
inhibited the increased frequency of rearing in the homozygous CCK2R-/- mice. 
Also, the highest dose of naloxone (10 mg/kg) did not induce a significant 
reduction of time in locomotion in the homozygous mice CCK2R-/- (Tukey 
HSD test: wild-type CCK2R+/+ mice P<0.05 and homozygous CCK2R-/- 




Figure 6. The effect of naloxone (1 and 10 mg/kg i.p.) on the locomotor activity of 
CCK2 receptor-deficient mice not adapted to the motility boxes. The number of animals 
in each group was eight. White bars – saline treatment, striped bars – naloxone (1 
mg/kg), black bars – naloxone (10 mg/kg). (*) P < 0.05 (compared with the saline-
treated mice, Tukey HSD test after the significant one-way ANOVA); (+) P < 0.05 
(compared with the saline-treated wild type mice). 
 
 
In mice, habituated to the experimental environment, the application of two-way 
ANOVA did not distinguish the action of naloxone in the wild-type CCK2R+/+ 
and homozygous CCK2R-/- mice (Figure 7.) (time spent in locomotion (two-
way ANOVA: genotype: F1,52=0.27, P=0.61; treatment: F2,52=4.06, P<0.05; 
genotype × treatment: F2,52=1.41, P=0.25); distance travelled (two-way 
ANOVA: genotype: F1,52=0.48, P=0.49; treatment: F2,52=6.44, P<0.01; 
genotype × treatment: F2,52=2.26, P=0.11); frequency of rearing (two-way 
ANOVA: genotype: F1,52=0.44, P=0.51; treatment: F2,52=1.08, P=0.35; 
genotype × treatment: F2,52=0.77, P=0.47) and number of corner entries (two-
way ANOVA: genotype: F1,52=0.38, P=0.54; treatment: F2,52=5.77, P<0.01; 
genotype × treatment: F2,52=1.06, P=0.35)). However, the situation was 
different after the post-hoc analysis. Naloxone (10 mg/kg) induced the 
inhibition of locomotor activity only in the homozygous CCK2R-/-, but not in 
the wild-type CCK2R+/+ mice (Tukey HSD test: time in locomotion, P<0.05; 
distance travelled, P<0.01, number of corner entries P<0.05) (Figure 7.). 
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Figure 7. The effect of naloxone (1 and 10 mg/kg i.p.) on the locomotor activity of the 
CCK2 receptor-deficient mice adapted to the motility boxes. The number of animals in 
each group was 9–10. White bars – saline treatment, striped bars – naloxone (1 mg/kg), 
black bars – naloxone (10 mg/kg). (*) P < 0.05 (compared with saline-treated homo-
zygous mice, Tukey HSD test after the significant one-way ANOVA). 
 
 
5.2. Behavioural sensitization (Papers III and IV) 
5.2.1. Behavioural sensitization with amphetamine (Paper III) 
A four-day treatment with saline did not affect the locomotor activity of the 
homozygous and wild-type animals (Figure 8). However, the repeated treatment 
with amphetamine (1 mg/kg) increased the locomotor activity of the mice 
compared to saline treatment. Although, the application of repeated measure 
MANOVA did not reveal any significant genotypic differences in action of 
amphetamine (total distance, MANOVA: genotype: F(1,49)=0.04, P=0.837; 
treatment: F(1,49)=0.89, P=0.349; day: F(1,49)=16.67, P<0.001; genotype × 
treatment: F(1,49)=0.86, P=0.36; genotype × day: F(1,49)=0,55, P=0.464; treatment 
× day: F(1,49)=15.78, P<0.001; genotype × treatment × day: F(1,49)=0.84, 
P=0.365); (number of corner visits: MANOVA: genotype: F(1,49)=0.05, 
P=0.825; treatment: F(1,49)=6.78, P=0.012; day: F(1,49)=17.00, P<0.001; 
genotype × treatment: F(1,49)=0.99, P=0.324; genotype × day: F(1,49)=1.14, 
P=0.292; treatment × day: F(1,49)=25.38, P<0.001; genotype × treatment × day: 
F(1,49)=0.29, P=0.593), the situation was a bit different after the post hoc 
analysis. The application of post hoc analysis revealed that the distance 
travelled was significantly increased in the homozygous mice, but not in the 
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wild-type animals. Taking into account the actual numbers, one can find that in 
the case of the wild-type mice the increase in distance travelled was only 15 m, 
whereas in the homozygous animals the respective value was 38 m. This is 
almost a 2.5-fold difference in the action of amphetamine if the response of the 
wild-type and homozygous animals is compared. The repeated amphetamine 
treatment, 1 mg/kg only tends to increase the total distance of movement of the 
wild-type mice, whereas in the knockout mice this dose caused a significant 
increase in this parameter of the locomotor activity by the forth administration if 
compared with the saline treated group of the same genotype (Newman-Keuls 
test, P 0.05). Also, the frequency of corner entries was more prominently 
increased in the homozygous mice compared to their wild-type littermates. In 
comparison with the saline treated animals, only the number of corner visits of 
the amphetamine treated wild-type mice was significantly grown by the forth 
day (Newman-Keuls test, P0.01). At the same time evoked the forth 
amphetamine administration in the knockout mice group a highly significant 















































Figure 8. Effect of repeated treatment of amphetamine (1 mg/kg) on the locomotor 
activity of the wild-type (wt) and homozygous (−/−) CCK2 receptors deficient mice. 
The number of mice in the saline-treated group was 13 and in the amphetamine-treated 
group 14. White bars: acute saline treatment; dark grey bars: 4-day saline treatment; 
pale grey bars: acute amphetamine treatment; black bars: 4-day amphetamine treatment. 
*P < 0.05; **P < 0.001 (compared with the repeated saline treatment of respective 
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Figure 9. Effect of rimonabant (1 mg/kg) on motor sensitisation to amphetamine (2 mg/kg). 
On days 1–4, vehicle or rimonabant and saline or amphetamine were injected 30 and  
0 min before testing, respectively. On day 25, amphetamine was injected immediately 
before testing. 
() P < 0.05; () P < 0.01 compared to the respective control group treated with vehicle 
and saline on days 1 - 4; Newman-Keuls test. 
(**) P < 0.01 compared to the 1st treatment day of the same group; Newman-Keuls test. 
(#) P < 0.05; (##) P < 0.01 compared to wild-type mice; Newman-Keuls test. N = 7–9 
mice per group. 
Effect of four consecutive treatments (1st day compared with 4th day). Three-way 
ANOVA with repeated measures. Genotype: F(1,56) = 0.62, P = 0.44; treatment: F(3,56) = 
11.99, P < 0.01; measurement: F(1,56) = 27.21, P < 0.01; genotype × treatment: F(3,56) = 
2.51, P = 0.17; genotype × measurement: F(1,56)=0.11, P=0.75; treatment × 
measurement: F(3,56)=14.81, P<0.01) genotype × treatment × measurement: F(3,56) = 
0.74, P = 0.53). 
Effect of amphetamine (2 mg/kg) after withdrawal (1st day compared with 25th day). 
Three-way ANOVA with repeated measures. Genotype: F(1,56) = 0.04, P = 0.85; 
treatment: F(3,56) = 6.06, P < 0.01; measurement: F(1,56) = 108.75, P < 0.01; genotype × 
treatment: F(3,56) = 2.57, P = 0.06; genotype × measurement: F(1,56) = 0.33, P = 0.57; 
treatment × measurement: F(3,56) = 16.44, P < 0.01; genotype × treatment × 
measurement: F(3,56) = 0.78, P = 0.51). 
 
 
5.2.2. Behavioural sensitization with amphetamine and  
the effect of rimonabant co-treatment (Paper IV) 
In the behavioural sensitisation test, the first administration of amphetamine  
(2 mg/kg) suppressed motor activity in the CCK2R–/– mice but not in the 
CCK2R+/+ mice. The ANOVA results have been given in the legend of Figure 9. 
Four subsequent amphetamine treatments induced a significant motor sensiti-
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sation in both the CCK2R–/– and CCK2R+/+ mice. However, in the CCK2R–/– 
mice receiving amphetamine, their motor activity measured on day 4 was less 
pronounced. Nevertheless, the effect of amphetamine was significantly stronger 
on the fourth day in these mice when compared to their first treatment with 
amphetamine (P=0.0001) and treatment with saline (P=0.0129) on the fourth 
day in the CCK2R–/– mice (Figure 9). Sensitisation to amphetamine was 
confirmed by injecting amphetamine 21 days after the last experiment. Both, the 
CCK2R–/– and CCK2R+/+ animals that had received amphetamine treatment for 
4 days, displayed significant motor sensitisation compared to their first 
treatment session and compared to the animals that were acutely treated with 
amphetamin after having previously received saline. Similar to day 4, the 
amphetamine-induced motor effect was weaker in the CCK2R–/– mice. Pre-
treatment with the CB1 receptor antagonist rimonabant at the dose of 1 mg/kg 
did not affect locomotion when given alone but inhibited the effect of 
amphetamine. The co-administration of rimonabant and amphetamine for 4 days 
completely blocked the stimulant effect of the dopamine agonist. When 
amphetamine was injected 21 days later, the CCK2R+/+ animals that were 
previously administered rimonabant and amphetamine did display motor 
sensitisation, but this sensitisation was significantly less pronounced than in the 
group receiving vehicle and amphetamine. Remarkably, in the case of the 
CCK2R–/– animals, previous co-administration of rimonobant with amphetami-






















Figure 10. Effect of amphetamine (1, 2 and 3 mg/kg) on the place preference of the 
wild-type (wt) and the homozygous (−/−) the CCK2 receptors deficient mice. White 
bars: saline (14 wild-type and 13 homozygous mice); dark grey bars: amphetamine  
1 mg/kg (9 wild-type and 8 homozygous mice); pale grey bars: amphetamine 2 mg/kg 
(7 wild-type and 8 homozygous mice); black bars: amphetamine 3 mg/kg (8 wild-type 
and 10 homozygous mice). *P < 0.05 (compared with the saline-treated wild-type mice, 
Newman–Keuls test after the significant two-way ANOVA). 
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5.3. Conditioned place preference with amphetamine 
(Paper III) 
In the conditioned place preference test during the pre-conditioning period both 
the wild-type and homozygous mice preferred to stay in the dark green 
compartment of the shuttle box (ANOVA: genotype: F(1,75)=0.067, P=0.798) 
(Figure 10). The pairing of pale green part with amphetamine injections 
significantly increased the preference of mice for this compartment (two-way 
ANOVA: genotype: F(1,69)=2.87, P=0.095; treatment: F(1,69)=6.34, P<0.001; 
genotype × treatment: F(1,69)=1.19, P=0.320). The application of post hoc 
analysis revealed that amphetamine induced a significant place conditioning in 
the wild-type mice, but not in the homozygous animals. Already 1 mg/kg of 
amphetamine tended to shift the preference of the wild-type mice into the pale 
green side and at the doses of 2 and 3 mg/kg induced a significant change in the 
place preference (Newman-Keuls test, P0.05). Amphetamine caused the 
strongest effect at the dose of 2 mg/kg in the wild-type mice. Amphetamine 
increased the time spent in the not-preferred side for 195 s in these animals. The 
respective difference for the homozygous mice was only 66 s. This demon-
strates almost a three-fold difference in the action of the drug. By contrast, in 
the homozygous mice even the highest dose of amphetamine (3 mg/kg) did not 
cause a significant shift (Newman-Keuls test, P=0.158) (Figure 10.). The 
pairing of the dark and pale green box with saline injections did not change the 
animals’ place preference compared to the pre-conditioning session (Paper III).  
 
 
5.4. Content of dopamine and its metabolites  
in the brain structures (Paper I) 
The assay of dopamine and its metabolite levels in the cerebral cortex, the 
striatum and the hypothalamus did not reveal significant differences between 
the CCK2R+/+ and CCK2R-/- mice (Table 4.). The number of mice in both 
genotype group was three. 
 
 




Cerebral cortex  Striatum  Hypotalamus 
+/+ -/-   +/+ -/-   +/+ -/- 
Dopamine 0.32±0.12 0.24±0.11   65.5±6.0 53.2±3.5   1.3±0.3 1.2±0.2 
DOPAC 0.42±0.06 0.30±0.10  4.7±0.2 5.4±0.8  0.4±0.03 0.43±0.01 
HVA 0.32±0.06 0.35±0.11   7.1±0.7 6.1±1.3   1.5±0.2 1.4±0.1 
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5.5. Radioligand binding data (Papers I an II) 
5.5.1. [3H]-spiperone binding in the brain (Paper I) 
The density of [3H]-spiperone binding sites was significantly higher in the 
striatum of the homozygous CCK2R-/- mice than their wild-type CCK2R+/+ 
littermates (Figure 11.). Also, in the mesolimbic structures, the number of [3H]-
spiperone binding sites was somewhat increased (not statistically significant) in 
the homozygous CCK2R-/- mice. A similar trend of increased [3H]-spiperone 
binding was apparent in the striatum of the heterozygous CCK2R+/- animals. In 
the cerebral cortex, we did not find any differences between the wild type 





Figure 11. The parameters of [3H]-spiperone binding in the brain structures of the 
CCK2 receptor-deficient mice. The number of animals in each group was 18, the brains 
of 6 mice were pooled, and the mean is the result of three experiments. White bars wild-
type, striped bars heterozygous, black bars homozygous. *P<0.05 (compared with the 




5.5.2. [3H]-diprenorphine binding in the brain (Paper II) 
The radioligand binding studies with [3H]-diprenorphine demonstrated an 
increase in the affinity of the opioid binding sites in the cerebral cortex of the 
mutant mice compared to the wild-type CCK2R+/+ littermates (Figure 12.). 
However, the decreased affinity and increased density of the opioid binding 
sites was established in the striatum of the homozygous CCK2R-/- mice. The 
parameters of [3H]-diprenorphine binding were not affected in the mesolimbic 
structures and the hippocampus.  
 
Figure 12. The parameters of [3H]-diprenorphine binding in the brain structures of the 
mice without CCK2 receptors. The number of animals in each group was 24, the brains 
of six mice were pooled, and the mean is the result of four experiments. White bars – 




5.6. Gene expression analysis (Paper III) 
We established a genotype-dependent difference in expression of Drd2 gene in 
the mesencephalon (Figure 13. A.). (two-way ANOVA: genotype: F(1,12) = 
10.61, P = 0.007; treatment: F(1,12) = 0.47, P = 0.507; genotype × treatment: 
F(1,12) = 1.6, P = 0.229). Indeed, the expression of Drd2 gene in the saline-
treated homozygous CCK2R-/- mice was significantly lower in comparison with 
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the wild-type animals (Newman-Keuls test, P0.05). Four-day administration of 
amphetamine induced changes in the expression of Comt gene (two-way 
ANOVA: genotype: F(1,12) = 0.59, P = 0.46; treatment: F(1,12) = 16.2, P <0.001; 
genotype × treatment: F(1,12) = 0.65, P = 0.44) and Tyhy gene (two-way 
ANOVA: genotype: F(1,12) = 0.09, P = 0.77; treatment: F(1,12) = 49.2, P <0.001; 
genotype × treatment: F(1,12) = 0.01, P = 0.93). The expression level of Tyhy 
and Comt genes in the amphetamine-sensitized mice of both genotypes was 
significantly higher compared to the respective groups of the saline-treated mice 
(Newman-Keuls tests, P0.001 and P0.05, respectively).  
In the striatum, we established a genotype-dependent effect of amphetamine 
treatment on the expression of Tyhy (Figure 13. B.) (two-way ANOVA: 
genotype: F(1,12) = 3.22, P = 0.11; treatment: F(1,12) = 0.55, P = 0.48; genotype 
× treatment: F(1,12) = 14.8, P = 0.005) and Drd1 (two-way ANOVA: genotype: 
F(1,12) = 2.36, P = 0.16; treatment: F(1,12) = 2.53, P = 0.15; genotype × 
treatment: F(1,12) = 17.8, P = 0.003) genes. Tyhy and Drd1 mRNA levels were 
significantly elevated only in the amphetamine-sensitized wild-type mice. By 
contrast, the level of these genes (Newman-Keuls test: Tyhy gene P0.05; Drd1 
gene P0.01) was markedly lower in the amphetamine-treated homozygous 
CCK2R-/- mice compared with the corresponding group of the wild-type 
animals. 
In the mesolimbic structures, we found treatment- and genotype-dependent 
changes of Tyhy (Figure 13. C.) (two-way ANOVA: genotype: F(1,12) = 5.48,  
P = 0.047; treatment: F(1,12) = 20.0, P = 0.002; genotype × treatment; F(1,12) = 
1.73, P = 0.23) and Drd2 (two-way ANOVA: genotype: F(1,12) = 24.3, P = 
0.001; treatment: F(1,12) = 6.36, P = 0.036; genotype × treatment: F(1,12) = 1.39, 
P = 0.27) gene expression. In this particular brain region Tyhy gene expression 
was significantly higher in the saline-treated homozygous CCK2R-/- mice 
compared to their wild-type littermates (Newman-Keuls test, P0.05). 4-day 
treatment with amphetamine in the wild-type mice induced a significant 
increase in the expression of Tyhy and Drd2 genes. At the same time, the 
expression level of Drd2 gene in the amphetamine-treated homozygous 
CCK2R-/- mice was significantly lower compared to the respective group of the 
wild-type animals (Newman-Keuls test, P0.01) (Paper III). 
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Figure 13. Effect of the repeated amphetamine (1 mg/kg) administration on the gene 
expression levels of the dopamine-related genes in the mesencephalon (A.), striatum 
(B.) and mesolimbic (C.) structures of the wild-type (wt) and homozygous (−/−) CCK2 
receptor deficient mice. Every experimental group (n = 13) was pooled as follows: three 
pools including samples from three mice and one pool including samples from four 
animals. The number of independent samples in each case was four. White bars: 
repeated saline treatment; black bars: repeated amphetamine treatment. *P < 0.05;  
**P < 0.01 (compared with the saline treated group of respective genotype, Newman–
Keuls procedure after the significant ANOVA); (+) P < 0.05; (++) P < 0.01 (compared 





6.1. Alterations in dopamine mechanisms due  
to the lack of CCK2R 
The genetic deletion of CCK2R causes alterations in the functions of the central 
dopaminergic system. The effects of two dopaminergic drugs, apomorphine, an 
unselective D1 and D2 receptor agonist, and amphetamine, a drug increasing the 
release of dopamine (DA) and noradrenaline from the presynaptic terminals 
(Fleckenstein et al. 2007), were studied in CCK2R deficient mice (Paper I). The 
treatment with apomorphine 0.1 mg/kg, reduces the motor activity of mice. The 
motor suppressant effect of apomorphine is believed to be caused by the 
stimulation of presynaptic somato-dendritic D2 auto-receptors located on the 
DA neurones (Meltzer 1980). The activation of dopamine autoreceptors located 
at the soma decreases the firing rate of dopaminergic neurons (Bunney et al. 
1973) and axon-terminal autoreceptors inhibit DA release (Cubeddu and 
Hoffmann 1982). In rats the systemic treatment with apomorphine induces 
suppression of cell firing in the VTA (Bortolozzi et al. 2007). The motor 
depressant effect of apomorphine 0.1 mg/kg was apparently stronger in the 
heterozygous CCK2R+/- and the homozygous CCK2R-/- receptor-deficient mice 
than their CCK2R+/+ littermates. The increased response is probably related to 
the increased sensitivity of the presynaptic DA receptors. This is in good 
agreement with some earlier pharmacological studies in which the pre-treatment 
of mice with the CCK2R antagonist L-365,260 potentiated the motor suppres-
sant action of apomorphine (Vasar et al. 1991). Moreover, electrophysiological 
studies in rats demonstrated that the acute and long-term administration of 
LY262691 and related pyrazolidinone CCK2R receptor antagonists decreased 
the number of spontaneously active DA cells in the midbrain structures, 
probably via action in the nucleus accumbens and the prefrontal cortex 
(Rasmussen et al. 1993). Also, it is proved that CCK2R stimulation functionally 
opposes the postsynaptic effects of DA in the nucleus accumbens (Weiss et al. 
1989; Yim and Mogenson 1991). The administration of amphetamine (3 mg/kg 
and 6 mg/kg) induced a dose-dependent motor stimulation in CCK2R+/+. 
However, in the mutant mice, the effect of amphetamine was different. In the 
heterozygous CCK2R+/- mice 3 mg/kg tended to increase their motor activity, 
but 6 mg/kg had the same effect as in the CCK2R+/+ mice. In the homozygous 
CCK2R-/- mice, the 3 mg/kg did not affect parameters of the horizontal 
locomotor activity. The treatment with the dose of 6 mg/kg induced a signifi-
cant increase in their locomotor activity. It should be noted that the effect of the 
dose of 6 mg/kg in the CCK2R-/- mice on these parameters was significantly 
higher from that seen in the heterozygous CCK2R+/- and wild-type animals. The 
increased response to amphetamine 6 mg/kg in the homozygous CCK2R-/- 
animals could be related to the increased activity of the postsynaptic DA 
receptors. Previous studies seem to support this hypothesis. The administration 
of CCK into the anterior NAc inhibits DA-induced hyperlocomotion, and this 
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effect is mediated via CCK2R (Crawley 1992; Dauge et al. 1990). However, the 
blockade of CCK2R in the NAc increases amphetamine-induced DA release 
and hyperlocomotion (Altar and Boyar 1989). Centrally administrated CCK2R 
agonists (BOC-CCK-4 or CCK-8U) attenuated DA release. To confirm an 
arisen idea about the altered activity of the mesolimbic dopaminergic neurons 
the content of DA and metasbolites in the cerebral cortex, the striatum and the 
hypothalamus, was measured. Nevertheless, despite the obvious dopamine 
related behavioural changes, the difference in the content of DA and metabolites 
between the CCK2R+/+ and CCK2R-/- mice brain samples, was not detectable 
(Paper I). However, in the radioligand binding study on the crude striatal and 
mesolimbic brain samples the increased density of the D2 receptors becomes 
evident. Earlier biochemical studies showed that CCK-8S through the activation 
of CCK2R decreases the affinity to D2 receptor agonists and special effects of 
the pre- and postsynaptic D2 receptors in the medial posterior-nucleus 
accumbens and caudate putamen (Dasgupta et al. 1996; Ferraro et al. 1996; Li 
et al. 1995). Our striatal preparations consisted mainly of dorsal striatal caudate-
putamen structures which are innervated by the primary motor cortex, the 
anterior premotor and cingulated areas, the substantia nigra pars compacta 
(subNc); and in turn projects to the globus pallidus, and the substantia nigra 
pars reticulata (subNr). The main structure in the mesolimbic preparations was 
NAc, which receives inputs from the mPFC, hippocampus, amygdala and VTA; 
and sends projections to the VP, the subNc, the VTA and the hypothalamus. 
The dorsal striatum is mainly related to the voluntary motor function, whereas 
the NAc is mostly an interface between the limbic and the motor system and 
plays a major role in motivated and goal directed behaviours (David et al. 2005) 
In the [3H] spiperone binding assay, we detected significantly increased density 
of the D2 receptors in the striatum of homozygous CCK2R
-/- mice relative to 
their wild-type littermates, and in the mesolimbic area a similar trend was seen. 
In the heterozygous CCK2R+/- mice, the density of D2 receptors was somewhat 
elevated in the striatum, but not at all in the mesolimbic area. No differences in 
the affinity to [3H] spiperone were observed (Paper I). Li and colleagues have 
demonstrated that CCK 8S induced the inhibition of D2 receptor affinity is 
larger in slice compared with the membrane preparation, suggesting that intact 
intracellular mechanisms and more intact membrane structure are required for 
an optimal CCK/D2 receptor-receptor interaction (Li et al. 1995). Moreover, the 
results of the gene expression studies were in line with the stimulated 
dopaminergic projections from the mesencephalon to the mesolimbic structures 
of the CCK2 receptor deficient mice (Paper III). Indeed, Drd2 was down-
regulated in the mesencephalon of the drug naïve homozygous CCK2R-/- mice. 
D2 receptors in the mesencephalon are DA autoreceptors. These receptors 
regulate the synthesis and release of DA and it has been suggested that auto-
receptor sub-sensitivity contributes to the enhanced release of DA (Pierce and 
Kalivas 1997). On the other hand, the expression of tyrosine hydroxylase gene, 
responsible for the synthesis of DA, was elevated in the mesolimbic structures 
of the drug naive genetically modified mice. The increased response to 
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apomorphine-induced motor suppression is probably related to the increased 
sensitivity of the striatal presynaptic DA receptors and a higher response to 
amphetamine in the homozygous CCK2R-/- animals is most likely related to the 
higher sensitivity of the striatal postsynaptic DA receptors, as the radioligand 
binding studies confirm. Moreover, Dauge and colleagues showed as well that 
the tone of dopaminergic system is increased in the forebrain structures of the 
male CCK2 receptor deficient mice and the stimulating effect of amphetamine 
on the motor activity is stronger in these animals (Dauge et al. 2001).  
 To confirm the findings of acute experiments, indicated the altered function 
of DA system, we studied the effect of the repeated treatment with 
amphetamine in the CCK2R-/- mice (Papers III and IV). Caudate-putamen is 
involved in the voluntary movement as well as in the initiation, production and 
sequencing of motor behaviour in the development of addiction, whereas the 
NAc plays a major role in motivated and goal directed behaviours and in the 
development and expression of addiction (David et al. 2005). Taking into 
account this information it was feasible to study the addictive potency of the 
amphetamine CCK2R-/- mice. The effect of amphetamine was studied in 
conditioned place preference and motor sensitization experiments (Papers III 
and IV).  
In the place conditioning test the effect of amphetamine was stronger in the 
wild-type CCK2R+/+ mice compared to their homozygous CCK2R-/- littermates 
(Paper III). Only 1 mg/kg of amphetamine tended to induce a shift in the place-
preference of the wild-type CCK2R+/+ mice, whereas even 3 mg/kg of 
amphetamine did not induce a significant change in the preference of the 
homozygous CCK2R-/- mice. We know from earlier that infusion of CCK into 
the VTA potentiates amphetamine-induced conditioned place preference (Pettit 
and Mueller 1989). In accordance with our study, this effect could be attended 
to the activation of CCK2R. It has been demonstrated that the place 
conditioning induced by amphetamine is mediated via the NAc, and D2 
receptors there have a role in the induction of psychostimulant-induced place 
preference. The brain stimulation reward from the lateral hypothalamus is 
significantly attenuated in mice, lacking D2 receptors (Elmer et al. 2005). In our 
study the repeated treatment with amphetamine caused a significant up-
regulation of Drd2 and Tyhy genes in the mesolimbic area of the wild-type 
CCK2R+/+ mice, but not in their homozygous CCK2R-/- littermates (Paper III). 
The increased dopaminergic neurotransmission via D2 receptors in the meso-
limbic structures in the wild-type mice may be a reason for the differences in 
amphetamine-induced place preference established in two genotypes. The 
amphetamine-induced elevation of expression of Tyhy and Drd1 genes in the 
striatum of the wild-type mice also may contribute to the stronger effect of DA 
agonist on the place conditioning in these animals. Dopaminergic mechanisms 
in the striatum have been shown to play an important role in habit formation 
and, therefore, in the development of addictive drug induced place preference 
(Gerdeman et al. 2003).  
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 The evidence comes from previous studies that CCK modulates 
amphetamine induced motor sensitisation in rodents. The co-administration of 
CCK1R antagonist devazepide with amphetamine prevents the development of 
sensitization to this DA agonist. The simultaneous administration of CCK2R 
antagonist L-365,260 with amphetamine potentiates amphetamine-induced 
hyper-locomotion (Alttoa and Harro 2004). We found that a four-day treatment 
with the sub-threshold dose of amphetamine (1 mg/kg) induced a stronger 
motor sensitization in the homozygous CCK2R-/- mice compared to their wild-
type CCK2R+/+ littermates (Paper III). The administration of amphetamine 
increased both the distance travelled and the number of corner entries in the 
CCK2R deficient mice. The latter measure can be taken as a sign of repeated 
stereotyped behaviour. In the wild-type CCK2R+/+ mice, only the number of 
corner entries was increased significantly. However, this elevation was not as 
marked as in the case of genetically modified mice. It has been shown that the 
VTA and mesolimbic dopaminergic system plays a major role in the 
development of sensitisation to the motor stimulant effect of amphetamine 
(Ben-Shahar and Ettenberg 1994). However, we found that the repeated 
administration of amphetamine induced a similar increase in the expression of 
Tyhy and Comt in the mesencephalon of both genotypes (Paper III). This is in 
line with the finding that chronic administration of amphetamine increases the 
levels of tyrosine hydroxylase, the rate-limiting enzyme in dopamine 
biosynthesis, in the VTA (Nestler 1992). The increase in the expression of Tyhy 
and Comt probably reflects an increase in the synthesis and metabolism of DA 
in the mesencephalon under the influence of amphetamine. The reason for a 
higher motor activity of the CCK2R-/- mice in this motor sensitisation 
experiment could be due to the altered dopamine D2 autoreceptors activity. In 
the wild-type CCK2R+/+ mice 4-day treatment with amphetamine induced a 
significant increase in the expression of Drd2 genes, but at the same time, the 
expression level of Drd2 gene in the amphetamine-treated homozygous 
CCK2R-/- mice was significantly lower compared to the respective group of the 
wild-type animals. This finding indicates to the lower DA autoreceptors activity 
in the CCK2R-/- mesencephalon and could be a reason for the stronger 
amphetamine induced motor sensitization in the homozygous CCK2R-/- mice. 
Many studies describe a critical role of mesencephalic A10 dopamine neurons 
in the induction of behavioural sensitization to amphetamine (Kalivas and 
Weber 1988; Vezina 1993; Vezina and Stewart 1989). 
 In the behavioural sensitisation test with 2 mg/kg amphetamine, the first 
administration suppressed the motor activity in the CCK2–/– mice but not in the 
CCK2+/+ mice (Paper IV). Four subsequent amphetamine treatments induced a 
significant motor sensitisation in both CCK2–/– and CCK2+/+ mice. However, in 
the CCK2–/– mice receiving amphetamine, the motor activity measured on day 4 
was less pronounced. Sensitisation to amphetamine was confirmed by injecting 
amphetamine 21 days after the last experiment. Both CCK2–/– and CCK2+/+ 
animals that had received amphetamine treatment for 4 days displayed a 
significant motor sensitisation and similar to day 4, the amphetamine-induced 
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motor effect was weaker in the CCK2–/– mice (Figure 9.). An explanation for a 
significantly weaker effect of the repeated treatment with amphetamine  
(2 mg/kg) in the CCK2–/– mice compared to their CCK2+/+ littermates might be 
the increased sensitivity of striatal pre-synaptic dopamine D2 receptors, but 




6.2. Alterations in endocannabinoid mechanisms due  
to the lack of CCK2R 
An important finding of the current study is that the co-administration of the 
CB1 antagonist rimonabant with amphetamine attenuated the development of 
dopamine agonist-induced motor sensitization in mice, supporting the role of 
eCBs in the mechanisms of amphetamine-induced sensitization (Paper IV). This 
effect was absent in the CCK2R–/– mice; thus, it could be hypothesized that the 
presence of CCK2R is necessary for the development of eCBs-mediated 
amphetamine-induced sensitization. The co-administration of amphetamine and 
rimonabant for 4 days significantly decreased the distance travelled compared to 
both CCK2R+/+ and CCK2R-/- animals treated with vehicle and amphetamine 
(Figure 9). Although the change was not statistically significant, rimonabant 
alone tended to decrease locomotion; one can speculate that this effect may 
have a non-specific origin. However, when animals were challenged with 
amphetamine 21 days later, the CCK2R+/+ animals previously administered 
rimonabant and amphetamine displayed a clearly attenuated response to the 
psychostimulant, demonstrating that sensitization had been inhibited by 
rimonabant. Interestingly, previous rimonabant treatment did not change the 
development of sensitization to amphetamine in the CCK2R-/- animals (Paper 
IV). Our study is in agreement with previous studies demonstrating that eCBs 
participate in psychostimulant-induced hyperactivity mechanisms. In these 
studies, the CB1 receptor-deficient animals and the animals treated with CB1 
antagonist were shown to be less responsive to the acute stimulating effects of 
amphetamine (Tzavara et al. 2009). Moreover, the invalidation of CB1 
receptors resulted in the loss of amphetamine (1 mg/kg)-induced locomotor 
sensitization (Thiemann et al. 2008). However, in the latter study, a higher dose 
of rimonabant (3 mg/kg) than that used in our study (1 mg/kg) augmented the 
development of amphetamine sensitization. These contradictory findings may 
be due to the fact that rimonabant is a mixed antagonist/partial agonist of CB1 
receptors that has been shown to induce hyperlocomotion with an ED50 of 4.7 
mg/kg (Compton et al. 1996).  
 The effect of rimonabant on the CCK2R–/– mice was somewhat different. On 
the fourth day, the CB1 receptor antagonist inhibited amphetamine-induced 
locomotion in the CCK2R-/- mice. However, the experiment performed 21 days 
after the last treatment with rimonabant revealed that an amphetamine challenge 
induced the same degree of hyperlocomotion in both groups of animals that 
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were previously administered rimonabant and amphetamine as well as animals 
that received vehicle and amphetamine. Thus, to block the development of 
sensitisation to amphetamine by rimonabant, intact CCK2R signalling is 
necessary. This finding is in agreement with our previous study demonstrating 
that CCK participates in the eCB-system activation involved in the development 
of stress-induced analgesia (Kurrikoff et al. 2008). However, Kurrikoff and 
colleagues (Kurrikoff et al. 2008) demonstrated that stress-induced analgesia 
was accompanied by the increased expression of CB1 receptor gene in the 
mesolimbic area of the wild-type mice. This effect was not noted in the 
CCK2R–/– mice. Therefore, it is possible that the genetic invalidation of the 
CCK2R alters eCB-mediated signalling in the mesolimbic structures.  
 
 
6.3. Alterations in endopiate mechanisms due  
to the lack of CCK2R 
Mutant male mice, lacking CCK2R and crossed back three times to the 
C57/BL6 background, displayed impaired motor ability (Paper I). The loco-
motor activity of the CCK2R+/- and CCK2R-/- mice tended to be lower than in 
their wild-type littermates after the administration of saline and, in one 
experiment, this difference reached a statistical significance. The motor 
impairment of the CCK2R+/- and CCK2R-/- male mice crossed back three times 
to the C57/BL6 background was revealed clearly in the rota-rod test (Kõks et al. 
2001). It is possible that the targeted mutation of CCK2R induces the motor 
disturbances in mice predominantly having the genes of a 129 SV strain. The 
vast majority of gene knock-out experiments have used a diverse collection of 
embryonic stem cells derived from sub-strain 129, and the phenotypic analysis 
is often confined to F2 hybrid mice derived by crossing the 129 cells derived 
chimeras with another inbred strain, typically C57BL/6 and the importance of 
this genetic background in the evaluation of complex behavioural traits in mice 
has also been convincingly proved. For example, the role of 129/SV or 
C57BL/6 genetic background of DA D2 deficient mice in open-field activity and 
rotarod performance has been characterised (Kelly et al. 1998). Congenic 
C57BL/6 homozygous D2 receptor deficient mice have higher locomotor 
activity and better performance in rotarod then congenic 129/SV homo-
zygousD2 receptor deficient mice. C57BL/6 mice show much longer latencies to 
fall than 129Sv mice in the rotarod test (Homanics et al. 1999). The further 
back-grossing of mice to the C57BL/6 background reversed this suppression of 
motor activity (Raud et al. 2003; Paper II and III). 
 Dauge et al. demonstrated that the basal locomotor activity of the CCK2R-/- 
male mice, previously not habituated to the test conditions, was increased 
compared to their wild-type CCK2R+/+ littermates (Dauge et al. 2001). The 
observed increase of the spontaneous motor activity in the CCK2R deficient 
mice compared with the wild-type CCK2R+/+ animals, was suppressed by the 
administration of the D2 receptos selective antagonist sulpiride, or of naloxone, 
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a nonselective competitive antagonist of opioid receptors (Dauge et al. 2001; 
Pommier et al. 2002). It could indicate that the elevation of this behavioural 
parameter in mice lacking CCK2R, is due to an increased function of endopioid 
and with its downstream related dopaminergic system. Differently from the 
study of Daugé et al. and Pommier et al. (Dauge et al. 2001; Pommier et al. 
2002) we were unable to find any significant differences in the horizontal 
component of the locomotor activity of the six times to the C57BL/6 
background back crossed wild-type and the mutant CCK2R-/- male mice, not 
habituated to the motility boxes (Paper II). In our experiment only the frequency 
of rearing was higher in mice without CCK2R. This discrepancy could be due 
to different experimental condition. It has been demonstrated that differences 
exist in behavioural results even in seemingly identical testing situation in 
different laboratories (Crabbe et al. 1999; Wahlsten et al. 2003). Dauge et al 
(2001) and Pommier et al. (2002) monitored horizontal movement of animals in 
dim plastic cages (255 x 205 cm) under the light intensity of 5 lux and in our 
experiment the illumination level of the transparent test boxes (44,8 x 44,8 x  
45 cm) was 400 lux. Locomotor activity in mice is sensitive to the context and 
both intra test and extra-test cues can influence behaviour. It is demonstrated 
that adult male C57BL/6 mice were in the dim open field more active, they 
covered a greater distance, moved faster and made more stops than in 
experiments under the bright light (Clark et al. 2006). 
In our study the higher motor activity of the CCK2R-/- male mice became 
evident after the habituation session (Paper II). The repeated exposure of mice 
to the motility boxes caused a significant reduction of the locomotor activity in 
the wild-type mice. The described behavioural change was significantly weaker 
in the mice lacking CCK2R. Central CCK- and endopioids are important factors 
in adaptation and are activated in a novel environment. For an illustration, CCK 
antagonises morphine-induced antinociception in a novel, but not in a familiar 
environment (Wiertelak et al. 1992). Also, morphine induces a significant 
anxiolytic-like action in rats, not habituated to the experimental conditions, 
whereas morphine was ineffective in habituated rats (Kõks et al. 1999; Kõks et 
al., 2000). Therefore, the lack of CCK2R, a subtype of CCK receptors 
preferentially distributed in the brain, apparently attenuates a normal adaptation 
to the novel environment. Differently from the study of Pommier and 
colleagues (Pommier et al. 2002) in our experimental design, only a higher dose 
of naloxone 10 mg/kg reduced the horizontal component of the locomotor 
activity in mice, and this effect was similar in the wild-type and mutant mice. 
Nevertheless, naloxone 1 mg/kg antagonised the increased frequency of rearing 
established in the homozygous CCK2R-/- mice showing that the elevation of this 
behavioural parameter is probably due to the increased function of the 
endopioid system in mice lacking CCK2R (Paper II). Moreover, we established 
that naloxone caused a different effect in the wild-type and homozygous 
CCK2R-/- mice adapted to the motility boxes. In these mice the high dose of 
naloxone (10 mg/kg) induced a significant inhibition of the locomotor activity 
in the CCK2R-/-, but not in the CCK2R+/+ mice. It has been shown that naloxone 
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at this high dose is lacking selectivity for the subtypes of opioid receptors 
(Tsuda et al. 1996). Nevertheless, it is likely that the impaired locomotor 
adaptation of the CCK2R-/- mice to the novel environment is due to the in-
creased function of the endopioid system.  
We also studied the effect of naloxone on the place aversion conditioning 
paradigm of the CCK2R-/- mice (Paper II). In the place aversion conditioning 
experiments naloxone 1 mg/kg tended to cause conditioned place aversion in 
the wild-type mice, whereas the dose of 10 mg/kg caused a significant place 
aversion. By contrast, the naloxone-induced place aversion was weaker in the 
CCK2R-/- mice, because this dose of naloxone only tended to shift the behaviour 
of mutant mice from the preferred to non-preferred side. Naloxone as an 
opioiod receptor competitive antagonist reduces the effect of endopioids in the 
central nervous system and the development of weaker place aversion in mutant 
mice may reflect an increased tone of the endopioid system in these mice. It was 
shown that naloxone 10 mg/kg failed to produce conditioned place aversion in 
mu-opioid receptor-deficient mice, whereas the effect of kappa-opioid agonist 
U50,488H remained unchanged (Skoubis et al. 2001). This finding obviously 
supports the involvement of mu-opioid receptors in the mediation of naloxone-
induced place aversion. This behavioural phenomenon can be induced by the 
local administration of naloxone into the VTA and NAc, but not into the 
striatum and medial prefrontal cortex (Shippenberg and Bals-Kubik 1995). 
Some evidence suggests that naloxone-induced action is not linked only to the 
mesolimbic dopaminergic system, because the blockade of mu-opioid receptors 
in the dorsal periaquaductal gray matter caused the conditioned place aversion 
(Sante et al. 2000). The role of periaquaductal gray matter in the regulation of 
pain sensitivity is well-known (Mason 1999). In the CCK2R-/- mice a significant 
reduction of pain sensitivity is established (Veraksitš et al. 2003) and therefore, 
it is possible to speculate that the increased tone of the endopioid system in this 
brain region could be linked to the reduced effect of naloxone in the CCK2R-/- 
mice. Moreover, to some extent this study tends to support the finding of 
pharmacological experiments showing that the CCK2R antagonists attenuate 
naloxone-induced place aversion in rats (Valverde and Roques 1998).  
The administration of morphine 5 mg/kg tended to increase the horizontal 
component of locomotor activity and significantly inhibited the frequency of 
rearing in the habituate CCK2R+/+ mice group. The higher dose of morphine,  
10 mg/kg, induced a significant hyper-locomotion in the wild-type animals. By 
contrast, in the CCK2R-/- mice this dose of morphine induced significantly 
weaker motor activation (Paper II). This finding contradicts with the study of 
Pommier and colleagues (Pommier et al. 2002) demonstrating that the 
administration of morphine (6mg/kg) and inhibition of enkephalin metabolism 
increases the locomotor activity in mice without CCK2R significantly more. 
The reason for these differences is unclear but could be attributed to a different 
research design and distinct genetic background of the mice used in these 
studies. Indeed, Pommier and colleagues (Pommier et al. 2002) found that the 
affinity and density of opioid receptors were not changed in the whole brain of 
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mice without CCK2R, however, we established a decreased affinity and 
increased density of the opioid binding sites in the striatum of CCK2R-/- mice 
(Paper II). We measured the density of opioid receptors by [3H]-diprenorphine 
in four distinct forebrain structures (the cerebral cortex, striatum, mesolimbic 
area, and hippocampus), and at least in these structures no decline in the density 
of opioid receptors was observed. Indeed, the number of opioid receptors was 
elevated in the dorsal striatum of mutant mice, whereas in the other structures 
no differences in the density of opioid receptors were established if the  
CCK2R-/- and wild-type animals were compared. On the other hand, the affinity 
of opioid receptors was reduced in the striatum. The reduced affinity of opioid 
receptors in the striatum could support the initial idea of Pommier and 
colleagues (Pommier et al. 2002) that the levels of endopioid peptides are 
increased in certain brain regions and therefore the affinity of opioid receptors is 
decreased. By contrast from the striatum the affinity of opioid receptors was 
increased in the cerebral cortex of the mutant CCK2R-/- mice compared to the 
wild-type littermates. It is shown that repeated treatments, daily multiple 
injection of escalating doses of morphine for few days; induced tolerance to 
locomotor effect of morphine; reduction the specific binding of [3H]-DAMGO 
in the VTA and [3H]-SCH2339 in the striatum, and an increase in the specific 
binding of [3H]-raclopride in the striatum, which were detected in the receptors 
autoradiography experiment (Le Marec et al. 2011). We established a higher 
density of the [3H]-spiperone binding sites in the CCK2R-/- mice dorsal striatum. 
These findings seem to support our hypothesis that a significantly weaker effect 
of morphine in the CCK2R-/-mice could be caused by chronically elevated 
levels of endoopioids in the CNS.  
The behavioural response to drugs of abuse is implicated to the mesolimbic 
dopaminergic pathways. The rewarding properties of opiates have been related 
to the changes in the mesolimbic dopamine activity (Wise and Bozarth 1987). 
Morphine has been shown to activate A 9 and A10 cells (Gysling and Wang 
1983) and as a result, it enhances dopamine release in the striatum (Di Chiara 
and Imperato 1988). GABA afferents in the VTA provides inhibitory feedback 
to A10 via spontaneous inhibitory postsynaptic potentials (Steffensen et al. 
1998). Mu-opioid receptors localised on GABA-ergic neurons are activated by 
opiates causing a hyperpolarisation that reduces GABA release, thereby 
disinhibiting dopamine cell firing (Johnson and North 1992; Leite-Morris et al. 
2002; Leite-Morris et al. 2004). Chronically elevated endogenous opioid 
peptide levels in the CCK2R-/- mice could have a direct connection to the 
altered function of the mesolimbic dopaminergic system of these mice. It is 
likely that these endopioids up-regulate dopaminergic activity by disinhibition 
of A10 neurons via inhibiting local GABAergic interneurons (Johnson and 
North 1992; Nugent et al. 2007) and the increased tone of the midbrain 
dopaminergic neurons could be a downstream effect of the elevated function of 
the endopioid system due to the targeted mutation of CCK2R. We did not find 
any differences in the content of DA and its metabolites and in the density of 
opioid receptors and D2 in the mesolimbic area, but the gene expression studies 
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reflect the increased tone of dopaminergic projections from the mesencephalon 
to the mesolimbic structures of the CCK2R-/- mice. Drd2 gene, dopamine 
auroreceptor gene, was down-regulated in the mesencephalon and on the other 
hand, the expression of Tyhy gene, responsible for the synthesis of DA, was 
elevated in the mesolimbic structures of the drug naive genetically modified 
mice (Paper III).  
 
 
6.3. Concluding remarks and future directions 
The results of the present study show that the targeted mutation of the CCK2R 
gene induces substantial alterations in the function of DA, endopioid, and eCBs 
systems. However, this is not surprising, because CCK is co-localised with 
dopamine and OP within the same neurones and brain regions (Hökfelt et al. 
1980a; Hökfelt et al. 1980b; Gall et al. 1987). Despite some discrepancies, 
probaby due to different experimental conditions, the results of the present 
study are in accordance with the earlier experiments conducted by Daugé and 
colleagues (Dauge et al. 2001; Pommier et al. 2002). Nevertheless, it should 
always be kept in mind that two mouse lines 129Sv and C57/Bl6, differing 
markedly by their behavioural and neurochemical parameters, are used for the 
generation of genetically modified animals. The evidence suggests that the 
genetic background has significantly stronger impact on the gene expression 
(Schalkwyk et al. 2007) and, therefore, on the behaviour of mice than the 
invalidation of certain genes (Abramov et al. 2008). Therefore, the genetic 
background of genetically modified mice has to be considered if their 
biochemical and behavioural phenotype is analysed. We found significant 
changes in the motor coordination and locomotor activity of mice with the 
dominating 129Sv genotype at the beginning of our study. It is well documented 
that the performance of 129Sv mice in the motor coordination and locomotor 
activity test is significantly inhibited compared to C57/Bl6 mice (Homanics et 
al. 1999; Võikar et al. 2001). The back-crossings to the C57/Bl6 genetic 
background apparently attenuated disturbances in the motor performance of the 
mice lacking CCK2R. However, as a matter of fact, only a part, but not all, of 
the effects induced by the targeted mutation of CCK2R are dependent on the 
genes of the 129Sv mice. 
The targeted mutation of CCK2R causes impaired adaptation to the novel 
environment. As mentioned above, the pharmacological, behavioural and 
molecular biology analysis revealed significant alterations in the activity of 
dopamine, encopioid, and eCBs systems in the CCK2R-/- mice. It is important to 
stress that the changes occurring in these neurotransmitter systems are not 
similar throughout the brain, because the established alterations are localized in 
discrete brain regions and therefore related to the distinct behaviours. The 
peculiarity of the behavioural outcome obtained from the CCK2R-/- mice is the 
combination of different integrated mechanisms. For example, the amphetamine 
induced sensitisation in the CCK2R-/- mice could be less sensitive to 
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rimonabant, because eCBs are produced in smaller amounts in the striatal 
neurons. The reason for that could be an increased activity of the signal 
transduction related to the endopioid and D2 receptors, as well as, the missing 
intracellular effect of the CCK2R activation.  
The opioid competitive antagonist naloxone diminished the increased 
locomotion, a sign of poor adaptation in the CCK2R-/- mice and a low dose of 
amphetamine reduced exploratory activity more in the mutant CCK2R-/- than in 
the wild-type CCK2R+/+ mice. Therefore, one could speculate that these homo-
zygous CCK2R-/- deficient mice have some behavioural similarities with the 
children having attention-deficit/hyperactivity disorder (ADHD). ADHD is a 
complex behavioural, emotional and cognitive disorder that is characterized by 
its core symptoms of impulsivity, hyperactivity, distractibility, inattentiveness 
and cognitive impairment. The neurobiological cause of ADHD probably lies, at 
least to major degree, within the dysregulation of the brain catecholaminergic 
systems in the prefrontal cortex and its connections to the striatal areas. It has 
been proposed that the inattentive subtype of ADHD may arise due to a 
dysfunction of dopamine functioning in the inhibitory control of the frontal 
cortex and the hyperactive/impulsive subtype due to impairment of functioning 
in subcortical structures (Heal et al. 2008). Taking into account the behavioural 
changes and alterations of the dopeminergic systems in the forebrain structures 
due to the invalidation of CCK2 receptors one could suggest these animals as a 
potential model for the preclincial study of ADHD. Indeed, further research has 
to be planned and performed in this direction.  
Moreover, as far as the DA system is concerned, the behavioural and bio-
chemical effects of distinct groups of antipsychotic drugs (including halo-
peridol, aripiprazole and olanzapine) have to be explored in these mice. It is 
interesting to stress that patients suffering from schizophrenia have an increased 
sensitivity to the DA receptors and an enhanced response to the psychotomi-
metic action of amphetamine (Gainetdinov et al. 2001). We have established 
something similar in mice lacking CCK2R. Taking into account the distinct 
changes in the effectiveness of morphine in the models of motor activity and 
place preference, it is of a great interest to explore the other motivational and 
addictive responses in the mice without CCK2R. In conclusion, we believe that 
this model can be of great importance for the pre-clinical screening of new 
drugs interacting with the neurotransmitter systems mediating motivational 




1. Genetic deletion of CCK2R in mice increases the activity of the midbrain 
dopaminergic neurons. Although the concentration of DA and its metabolites 
in the brain tissue was not changed, the gene expression studies were in line 
with the pharmacological and behavioural experiments indicating enhanced 
activity of dopaminergic projections.  
2. Pharmacological testing demonstrated that lack of CCK2R leads to the 
functional augmentation of the endopioid system and, therefore, changes the 
adaptation of mice in a novel environment. 
3. The CCK and eCBs play a role in the development of amphetamine induced 
sensitization and intact CCK2R are necessary for the mediation of eCBs 
effect on the development amphetamine-induced sensitisation. 
 
Genetic invalidation of CCK2R demonstrates that CCK plays a distinct role in 
the regulation of behaviours in the brain, it includes the regulation of motor, 
emotional and motivational mechanisms. Therefore, this animal model has 
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SUMMARY IN ESTONIAN 
 
Dopamiini, endopioidi ja endokannabinoidi  
süsteemide funktsionaalsed muutused CCK2 retseptori 
puudulikkusega hiirtel 
Koletsüstokiniin (CCK) on imetajate kesknärvisüsteemis laialdaselt levinud 
peptiidne neuromediaator, mis kaasmediaatorina osaleb erinevate kesknärvi-
süsteemi funktsioonide (hirm, valu, küllastustunne, motivatsioonide kujune-
mine, mälu, õppimine) regulatsioonis. Käesoleva töö eesmärk oli uurida 
CCKergilise süsteemi koostoimet dopamiinergilise, opioidergilise ja endo-
kannabinoidergilise süsteemiga, rakendades selleks transgeense tehnoloogia 
võimalusi, hiirte käitumise uurimist, farmakoloogilisi ja molekulaarbioloogilisi 
teste. Täpsemateks eesmärkideks oli selgitada CCK2 retseptori geneetilise 
puudulikkusega (CCK2R-/-) isastel hiirtel: 1) CCK ergiliste mehhanismide mõju 
aju dopamiinergiliste neuronite funktsioonile; 2) kuidas CCK2 retseptorite 
(CCK2R) geneetiline väljalülitamine muudab endopioidide süsteemi aktiivsust 
ja hiirte adaptatiivset käitumist; 3) endokannabinoidide rolli amfetamiini poolt 
indutseeritud sensibilisatsiooni kujunemises ning CCK2R võimalik seos sellega. 
Selgus, et CCK2R geneetiline väljalülitamine põhjustab funktsionaalseid 
muutusi hiirte mesolimbilises dopamiinergilises süsteemis. CCK2R-/- hiirte 
suurenenud tundlikus mitteselektiivse dopamiini D1 ja D2 retseptorite agonisti 
apomorfiini motoorikat pärssiva toime suhtes, viitab presünaptiliste D2 
retseptorite funktsiooni suurenemisele. Sünapsidest dopamiini vabastava 
amfetamiini annuse 3 mg/kg motoorikat stimuleeriv toime oli CCK2R-/- hiirtel 
nõrgem ja annuse 6 mg/kg toime tugevam kui nende CCK2 retseptoriga 
(CCK2R+/+) pesakaaslastel. See viitab postsünaptiliste dopamiinirtetseptorite 
tundlikkuse muutusele. Radioligandi sidumiskatse tulemused näitasidki 
CCK2R-/- hiirtel dorsaalses juttkehas suuremat D2 retseptorite tihedust. Kuigi 
dopamiini ja selle metaboliitide taseme määramisel erinevates ajustruktuurides 
muutusi ei ilmnenud, siis lisaks farmakoloogilistele käitumiskatsetele toetasid 
ka geeniekspressiooni analüüsi tulemused hüpoteesi, et CCK2R-/- hiirtel on 
mesolimbilistes struktuurides tõusnud dopamiinergiliste neuronite tooniline 
aktiivsus. Näiteks leidsime keskajus madalama dopamiini D2 retseptorite 
mRNA taseme ja ventraalses juttkehas tõusnud türosiinihüdroksülaasi mRNA 
taseme. Keskaju D2 retseptorid on põhilises osas dopamiinergilistele neuronitele 
negatiivset tagasisidekontrolli pakkuvad autoretseptorid ja türosiinihüdroksülaas 
on ensüüm, mis määrab dopamiini sünteesi aktiivsuse. 
Mesolimbiline dopamiinergiline süsteem täidab keskset rolli sõltuvushäirete 
tekkes ja seetõttu uurisime amfetamiini sõltuvust tekitavat toimet CCK2R-/- 
hiirtel. Selgus, et amfetamiini kohaeelistust tingiv toime nendel hiirel oli 
vähenenud. Motoorse sensibilisatsiooni testis omasid erinevad annused erinevat 
toimet. CCK2R-/- hiirte sensibilisatsioon amfetamiini annusega 1 mg/kg 
põhjustas suurema motoorse aktivatsiooni ja annus 2 mg/kg väiksema motoorse 
aktivatsiooni kui nende CCK2R+/+ pesakaaslastel. Geeniekspressiooni analüüs 
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näitas, et sensibiliseerimine amfetaminiga 1 mg/kg põhjustas CCK2R+/+ hiirtel 
dorsaalses juttkehas D1 retseptorite ja ventraalses juttkehas D2 retseptorite 
mRNA taseme olulise tõusu, CCK2R-/- hiirtel aga mitte. Samas tuleb arvestada, 
et lisaks muutunud dopamiini retseptorite tundlikkusele võivad mõjutused tulla 
ka mujalt, mittedopamiinergilistest mehhanismidest. 
Uurisime näiteks endokannabinoidide võimalikku rolli amfetamiinist 
tingitud motoorse sensibilisatsiooni tekkes, kasutades selleks rimonabanti, 
endokannabinoidide CB1 retseptori konkureerivat antagonisti. Eelnev rimona-
bandi manustamine pärssis CCK2R+/+ hiirtel sensibilisatsiooni väljakujunemist, 
CCK2R-/- hiirtel aga mitte. Kakskümmend üks päeva peale sensibiliseerimist 
manustatud ühekordne amfetamiini annus (2 mg/kg) põhjustas sensibilisee-
rimise perioodis amfetamiinile eelnevalt rimonabanti saanud CCK2R+/+ hiirtel 
oluliselt väiksema motoorse aktivatsiooni kui sama genotüübiga vaid amfeta-
miiniga sensibiliseeritud hiirtel. CCK2R-/- hiirel põhjustas aga kakskümmend 
üks päeva peale sensibiliseerimist manustatud ühekordne amfetamiini annus (2 
mg/kg) nii sensibiliseerimise perioodis amfetamiinile eelnevalt rimonabanti 
saanud hiirel, kui ka vaid amfetamiini saanud hiirel ühesuguse motoorse 
aktivatsiooni. See viitab endokannabinoidide osalusele amfetamiinist tingitud 
sensibilisatsiooni mehhanismides ning, et nende mehhanismide käivitumine 
eeldab toimivat CCK2R poolt vahendatud signaaliülekannet. Mesolimbiliste 
dopamiinergiliste neuronite toonilist aktiivsust võib suurendada ka tõusnud 
endopioidide süsteemi aktiivsus. CCK2R-/- hiirel esines väiksem keskkonnaga 
adaptatsiooni võime. Uudse keskkonna korduval eksponeerimisel hiirtele 
toimus selles keskkonnas olevate CCK2R+/+ hiirte motoorse aktiivsuse vähe-
nemine, CCK2R-/- hiirtel jääb aga motoorne aktiivsus oluliselt kõrgemaks. 
Motoorse aktiivsuse erinevuse kõrvaldas -opioidretseptori konkureeriva anta-
gonisti naloksooni manustamine. See viitab võimalusele, et suurem motoorne 
aktiivsus on tingitud kõrgemast endopioidide aktiivsusest CCK2R-/- hiirte 
kesknärvisüsteemis. Endopioidi-süsteemi aktiivsuse muutusele viitab ka erinev 
motoorne reaktsioon morfiini erinevatele annustele ning radioligandi 
sidumiskatsega leitud suurem opioidiretseptorite afiinsus ajukoores ning suurem 
tihedus ja väiksem afiinsus CCK2R-/- hiirte dorsaalses juttkehas. Opiaatide 
motoorset aktiivsust suurendav toime põhineb mesolimbiliste dopamiinergiliste 
neuronite aktiivsuse tõstmisel. Opiaadid pidurdavad tooniliselt aktiivseid 
GABA-ergilisi vaheneuroneid, mis kontrollivad vaheajus dopamiinergiliste 
neuronite aktiivsust. See tähendab, et CCK2R geneetiline väljalülitamine tingib 
muutusi nii dopamiinergilise, enendokannabinoidergilise ja ka opioidergilise 
süsteemi talitluses. Muutuste põhjused võivad olla otsesed, CCK2R poolt 
vahendatud mediaatorite sünteesi ja vabanemist reguleeriva signaali puudumine, 
või hoopis kaudsed, tingitud erinevate mediaatorsüsteemide muutunud koos-
toimest. Töö tulemused kinnitavad, et CCK omab kindlat rolli hiirte käitumise 
motoorsetes, emotsionaalsetes ja motivatsioonilistes mehhanismides ja, et 
CCK2R-/- hiired võivad osutuda potentsiaalseteks mudeliteks erinevate 
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